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iNTRODUCTION 
lymphoid organs are generally subdivided into two groups according to 
their contribution to antibody formation: 'primary 1 and 'secondari lymphoid 
organs. In mammals bone marrow and thymus are considered to be 'primar/ 
because these organs are involved in the generation of lymphocytes: B cells 
and T cells respectively. These lymphocytes can ieave t·heir place of origin 
and provide for antibody formation in secondary lymphoid organs: sp!een, 
lymph nodesr Peyer 1s patches and other gut-associated lymphoid tissue. 
After antigenic stimulation B cells can potentialfy differentiate into anti-
body producing plasma cells. T cells play a principal role in cell-mediated 
immune responses, which include delayed hypersensitivity, contact sensitivity, 
graft rejection, graft-versus-host responses and acquired resistance to some 
microbes. In addition to be involved in cell-mediated immunity T cells 
cooperate with B cells in antibody formation to most antigens. Thereby T cells 
can enhance and suppress the response of the B cells to the antigen. Antigens 
which reguire cooperation of B cells and T celfs to evoke antibody formation 
are called 1thymus-dependent 1 antigens in contrast to 1thymus-independent 1 
antigens which do not require T cells for antibody formation. 
There are suggestions in the I iterature that antibody formation in mammals 
can take place not only in secondary lymphoid organs but also in bone marrow: 
• (l) extracts of bone marrow from immunized guinea pigs and rabbits contained 
antibodies {1-lO), 
(2) bone marrow cells cultivated in vitro produced (6-21) and released 
{9, 11, 13, 14, 17-25) antibodies {6-14, 17, 18, 20, 22-24) and immuno-
globulins {7, 12-16, 19-21, 25), 
(3) studies in rabbits (26-29) and in man {30, 31) provided evidence for a 
positive correlation between the plasma cell content of the bone marrow 
and the serum titre after intensive antigenic stimulation, 
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(4) the bone marrow of immunized rabbits and mole rats contained antibody-
forming cells as determined with the plaque-assay (32-35), 
(5) in man a striking similarity was found between the percentage distribution 
of cells of the lymphoid series in the bone marrow which are positive for 
the various heavy and I ight chains and the percentage distribution of the 
heavy and I ight chains in the serum (36-42). 
Some of these studies go as far as to suggest that bone marrow is· the major 
source of serum antibodies (13, 33, 35) and immunoglobulins (13, 25, 36-43). 
Antibody formation by bone marrow cells of the mouse has been studied 
exclusively by means of the plague-assay. Only small numbers of antibody 
forming cells (PFC) have been found in the bone marrow of immunized mice 
(44-54). In some studies (44, 45, 47, 49, 51) a small but significant lgM-, 
lgG- and lgA-PFC response could be demonstrated some weeks after a single 
injection of antigen. Antibody formation in mouse bone marrow has also been 
studied during the secondary (44, 54) and tertiary (48) response. After multiple 
injections of the antigen small numbers of PFC in the bone marrow also appeared 
during the early phase of the response. 
The above studies with mice by no means suggest a substantial contribution 
of the bone marrow to total antibody synthesis. In view of these conflicting 
results as compared with studies on bone marrow of other species, We felt 
it worthwhile to reinvestigate the mouse bone marrow as a source of antibody-
forming cells. After having established that the bone marrow of mice can show 
a clear PFC activity after two intravenous (i.v.) injections of sheep red blood 
cells (SRBC), we started to investigate the underlying mechaniSm. In this thesis 
guantitative data on antibody formation in mouse bone marrow and its under-
lying mechanism will be presented. 
INTRODUCTION TO THE PAPERS 
The I iterature suggests migration of antibody-forming cells from secondary 
lymphoid organs into the bone marrow to be the underlying cause for anti-
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body formation in this organ (10, 18, 21, 35, 38, 43, 45). Research into the 
mechanism which accounts for antibody formation in the bone marrow is fa-
cilitated when only a small number of organs is involved in the antibody 
response. After i .v. injection of mice with moderate d~ses of antigen, lymph 
nodes and gut-associated lymphoid tissue do not generate antibody forming 
cells. Therefore in our studies on antibody formation in mouse bone marrow the 
antigen was injected almost exclusively i.v. 
In the graphs PFC activity in various lymphoid organs is given as the num-
ber of PFC per organ. This enables comparison of the contribution of the dif-
ferent lymphoid organs to the total PFC activity of the animal. Bone marrow 
PFC activity was determined in the femoral marrow. The PFC activity of the 
femoral bone marrow appeared to be representative for the PFC activity of 
the total marrow since the proportional PFC responses evoked by bone marrow 
cells from femur, tibia, humerus, sternum and rib did not differ significantly 
(appendix publications IV and V). For our calculations of the total bone marrow 
PFC activity we made use of the results of Chervenick and coworkers (55). 
In a detailed study these authors demonstrated with 59Fe-labelling that one 
femur of a mouse contains 5.9 per cent of its marrow. Using the same method 
agree very ather investigators found percentages of 6 (56) and 7 (57), which 
well with Chervenick's data. Although the distribution of 
59
Fe is not necessa-
rily representative for the distribution of PFC, it gives an approximation of 
the total amount of bone marrow. 
In appendix publication I experiments are described which show that mouse 
bone marrow can contain a substantial number of lgM-, lgG- and lgA-produ-
cing PFC after immunization with SRBC. This result was not found before the 
second i.v. injection of the antigen. During the first phase of the secondary 
response the spleen contained the majority of the total number of PFC. In the 
course of the reaction, however, the bone marrow became the major source of 
PFC. In this paper evidence is presented that the PFC activity in the bone 
marrow is caused by differentiation of non-antibody-producing cells into PFC 
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within the bone marrow in situ. 
The presence of_ a clear anti-SRBC PFC response in mouse bone marrow 
during the secondary response might be related to the generation of memory 
cells after the first injection of the antigen. In appendix publication II this 
possibility is investigated by means of cell transfer experiments. The results 
show that after a single i.v. injection of SRBC, specific B- and T-memory 
cells appear in the bone marrow. Thus the capacity of mouse bone marrow to 
show PFC activity during the secondary response to SRBC coincides with the 
presence of B- and T-memory cells within this organ at the moment of the 
second antigen injection. It is suggested in this paper that after a second 
injection of SRBC lgM-, lgG- and lgA-memory cells are stimulated to diffe-
rentiate with the help of T-memory cells within the bone marrow into lgM-, 
lgG- and lgA-PFC respectively. 
In appendix publication Ill the influence of the route of priming and dose 
of SRBC on the secondary bone marrow PFC activity was studied. It was found 
that priming via other routes than i.v. could also provide for secondary bone 
marrow PFC activity after an i.v. booster dose, because after intraperitoneal or 
subcutaneous priming bone marrow PFC occurred as well during the secondary 
response. 
From the data presented in appendix publication I it cannot be excluded 
that PFC activity in the bone marrow during the secondary response is a 
rather extraordinary phenomenon, attributable to the high doses of SRBC used 
in these studies. Appendix publication Ill shows data which indicate that the 
threshold booster dose of SRBC for spleen and bone marrow is about the same. 
This suggests that antibody formation to SRBC in mouse bone marrow during the 
secondary response is a regular phenomenon. 
Appendix publication IV deals with the influence of splenectomy an the 
bone marrow PFC response to SRBC. Splenectomy before priming with an opti-
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mum dose of 107 SRBC i .v. completely prevented bone marrow PFC activity 
during the secondary response. Cell transfer experiments revealed that splenec-
tomy before priming with 107 SRBC i.v. also prevented the appearance of B-
and T-memory cells in the bone marrow. This influence of splenectomy on both 
the appearance of B- and T -memory cells and the secondary bone marrow PFC 
activity could be partly overcome by priming with a higher antigen dose of 
4 x 10
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SRBC i.v. These results provide evidence that antibody formation in 
mouse bone marrow is dependent on the presence of memory cells. Secondary 
lymphoid organs are probably essential in order to generate these memory cells. 
Thorbecke et al. (17) reported that the thymus-independent (58) antigen 
Brucella, in contrast to thymus-dependent antigens (10, 17), can evoke anti-
body formation in rabbit bone marrow during the primary response. Therefore 
we decided to study antibody formation in the bone marrow of the mouse in 
response to a thymus-independent antigen. In appendix publication V anti-
body formation in mouse bone marrow was studied during the primary and se-
condc;try response to the thymus-independent antigen Escherichia coli lipopoly-
saccharide (LPS). In contrast to SRBC, antibody formation in the marrow to LPS 
appeared to occur not only during the secondary response but also during the 
primary response. 
The data presented in the appendix are reviewed in the next chapter. 
Three possible mechanisms for antibody formation in mouse bone marrow are 
suggested and briefly discussed. 
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DISCUSSION 
A simple method to demonstrate antibody-producing cells is the plaque-assay. 
In this assay cells secretin9 specific antibodies can be quantified easily (52). 
Using the plaque-assay we found that mouse bone marrow can contain large 
numbers of antibody-forming cells after i.v. immunization with the thymus-
dependent antigen SRBC (appendix publications I, Ill, IV) and the thymus-
independent antigen!.: coli LPS (appendix publication V). We could demon-
strate lgM- as well as lgG- and lgA-producing PFC in the marrow. Recently 
Kind and Malloy (59) reported the production af lgE-antibodies by adoptively 
transferred mouse bone marrow cells. Apparently mouse bone marrow can act 
not only as a primary but also as a secondary lymphoid organ. 
Some studies on antibody formation (13, 33, 35) and immunoglobulin synthesis 
(13, 25, 36-43) by bone marrow cells from guinea pig (13), mole rat (33), 
rabbit (35) and man (25, 36-43) suggest that the marrow might be a major 
source of antibodies. Our experiments on the bone marrow PFC response after 
i.v. immunization of mice with SRBC and LPS provide evidence supporting 
this supposition. During the second phase of the secondary response to SRBC 
(appendix publications I, Ill and IV) and the response to high doses of LPS 
(appendix publication V) we found up to ten times as many PFC in the marrow 
as in all the other lymphoid organs together. In considering these results it 
should be kept in mind that in our studies the last antigen-injection before 
studying the bone marrow PFC response was always given i.v. The contribution 
of the bone marrow to the total PFC activity after other routes of antigen-
administration remains to be determined. 
Recently Blijham (35) studied the PFC activity of various lymphoid organs of 
the rabbit during the primary and secondary response to SRBC. During the second 
phase of both the primary and secondary response he found more PFC in the 
bone marrow than in all other lymphoid organs together. Primary and secondary 
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PFC activity of the rabbit marrow were found to be at least partly dependent 
on other lymphoid organs: splenectomy before the first i.v. antigen-admini-
stration diminished the bone marrow PFC response, thereby suggesting that the 
PFC activity in the rabbit marrow was caused by migration of antigen-activated, 
possibly antibody-producing, cells into the bone marrow (35). 
It is worth noting that in both Blijham 1s studies with rabbits and our studies 
with mice the spleen was found to be the site where PFC appeared at first 
and the bone marrow appeared to be the organ which contained by far the 
greatest number of PFC during the second phase of the response. This suggests 
that these organs have a different task during the immune response after i.v. im-
munization. The spleen provides for the first attack on the invading antigens, 
and the bone marrow takes care of the greater part of the long term produc-
tion of protecting antibodies, thereby enabling the spleen to prepare for new 
antigenic experiences. The high bone marrow PFC activity and the decreased 
number of PFC in the spleen during the second phase of the response are pro-
bably due to regulating factors in these organs. Recently it was reported that 
bone marrow cells can synthesize a humoral factor which enhances the PFC 
response in cultures of lymph node cells obtained from immune donors at the 
peak of the productive phase of antibody formation (60). This factor might 
account for the high PFC activity observed in the bone marrow. On the 
other hand, the spleen of immunized mice was found to contain a factor 
which could effectively suppress the in vitro PFC response of spleen cells 
(61, 62). This factor might provide for the decrease of the splenic PFC activi-
ty during the second phase of the response. 
The other primary lymphoid organ, the thymus, also showed PFC activity 
after i.v. immunization with SRBC {appendix publication Ill) and LPS {appendix 
pub] ication V). PFC activity in response to both antigens was found only 
during the secondary response and after a high booster dose of antigen. In con-
trast to the bone marrow the thymus contributed only marginally to the total 
PFC activity in the mouse. 
The results presented in the appendix of this thesis do not comp~etely clarify 
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the mechanism underlying antibody formation in mouse bone marrow. Insight 
into this mechanism is especially hampered by our observation that different 
antigens evoke a bone marrow PFC response under different conditions. So far 
we have only tested one large-particulate thymus-dependent antigen with 
various antigenic determinants (SRBC) and one small-particulate (63) thymus-
independent polymeric antigen (LPS). Based upon the results obtained after 
immunization with these antigens, three possible mechanisms for antibody for-
mation in mouse bone marrow are suggested and briefly discussed. 
1. Antibody formation in mouse bone marrow is dependent on migra-
tion of antibody-forming cells from lymphoid organs such as spleen 
and lymph nodes into the bone marrow. 
This possibility has been suggested in the literature (10, 18, 21, 35, 38, 43, 
45) and is consistent with the following observations: (1) during the immune 
response cells which produce antibodies during in vitro cultivation appeared 
later in b?ne marrow than in spleen {9); (2) immunoglobulin-containing cells 
(42, 43, 64, 65) and PFC (32, 54, 66) are found in blood and lymph; (3) after 
bone marrow and thymus transplantation in a boy with severe combined immuno-
deficiency desease increased numbers of cells showing cytoplasmic immunoglo-
bulins appeared in the peripheral blood before a rise of immunoglobulin-con-
taining cells could be found in the bone marrow {65); (4) during ontogeny of 
mice immunoglobulin-containing cells were found to appear in spleen before 
they could be demonstrated in the bone marrow {67); (5) splenectomy before 
i.v. immunization with SRBC diminished the PFC activity in the bone marrow 
of rabbits (35); and (6) after immunization of mice with ovalbumin (59), SRBC 
(appendix publications I, Ill and IV) and LPS (appendix publication V) the 
appearance of antibody-forming cells in the bone marrow was delayed compared 
with the spleen. 
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2.Antibody formation in mouse bone marrow is dependent on initiation 
of an antibody-forming cell response by an antigen within the bone 
marrow. 
This hypothesis, which has been our working hypothesis throughout the expe-
riments, implies that the presence within the bone marrow of the lymphocytes 
involved in this antibody-forming cell reponse is a prerequisite. B cells spe-
cific for a variety of antigens (68), including LPS (appendix publication V), 
are present in normal mouse bone marrow. T cells, on the other hand, are 
scarce in this organ (68, 69). Therefore this second mechanism is consistent with 
our observation that during the primary response mouse bone marrow can exhibit 
PFC activity to the thymus-independent antigen LPS (appendix publication V), 
whereas it did not contain a substantial number of PFC after a single injection 
of the thymus-dependent ontige.n SRBC (appendix publications I and IV). 
Due to scarcity of T cells in mouse bone marrow, cells from this organ can 
barely evoke antibody formation to thymus-dependent antigens in lethally 
irradiated recipients (68, 70-79). After immunization increased numbers of antigen-
specific B cells appear in the bone marrow (80). Marrow cells from animals pre-
viously immunized with a thymus-dependent antigen, do produce antibodies in 
irradiated recipients, when these cells are transferred together with the priming 
antigen (70-73, 78). This observation suggests that after immunization not only 
increased numbers of B cells, but also T cells appear in the marrow. We con-
firmed these studies using SRBC as an antigen (appendix publications II and IV). 
In additinn we showed that both B- and T-memory cells in the bone marrow are 
antigen-specific (appendix publication II). The presence of SRBC-specific B-
and T -memory cells in mouse bone marrow coincided with the capacity of this 
organ to show PFC activity after a booster injection of SRBC (appendix publi-
cations II and IV). Moreover we found a positive correlation between the num-
ber of B- and T-memory cells in the bone marrow and the height of the secon-
dary bone marrow PFC response {appendix publication IV). Therefore the second 
mechanism for antibody formation in mouse bone marrow is consistent with the 
appearance of a distinct anti-SRBC response in the marrow only after a booster 
injection of SRBC. 
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3.Antibody formation in mouse bone marrow is dependent on migration 
of non-antibody-forming cells from lymphoid organs such as spleen 
and lymph nodes into the bone marrow during the response. 
The migrating lymphocytes are stimulated by antigen outside the 
bone marrow, but differentiation and maturation into antibody-
forming cells occur within the marrow. 
This third mechanism, which is a variant of the first one, has been suggested 
by Langevoort et al. (10). It is consistent with: (l) the appearance of immuno-
globulin-containing cells in the spleen before they could be demonstrated in 
the bone marrow during ontogeny (67); (2) the impaired PFC activity in the 
bone marrow of rabbits which were splenectomized before i.v. antigen-admini-
stration (35); and (3) the delayed appearance of antibody-forming cells in the 
bone marrow as compared with the spleen (9, 35, 59, appendix publications 
I and 111-V). The appearance of a distinct anti-SRBC PFC response in mouse 
bone marrow only after multiple injections of SRBC (appendix publications 
I, Ill and IV) is difficult to explain with this mechanism. Possibly T-memory 
cells in the bone marrow are required for the further differentiation of the 
incoming antigen-activated cells. 
The results presented in the appendix publications of this thesis are at va-
riance with the first mechanism suggested. In our experiments anti-SRBC (appen-
dix publications I and IV) and anti-LPS (Benner and van Oudenaren, to be 
published) bone marrow PFC responses could occur in the absence of PFC in 
all other lymphoid organs. Therefore migration of antibody-forming cells into 
the bone marrow as the underlying cause for bone marrow PFC activity appears 
not to be essential. This is consistent with studies on the migration of lymphoid 
cells in parabiotic mice. Ropke and Everett (81) studied the migration of cells 
by giving 3H-thymidine injections to only one member of a pair and preven-
ting escape of the radioactive isotope to the other member. They found only 
very few labeled immunoblasts and mature plasma cells in the bone marrow of 
the non-injected members as compared with the injected members. 
While the first possibility that antibody-forming cells migrate into the bone 
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marrow has been proven to be improbable, our experiments do suggest migra-
tion of cells to be essential for antibody formation in mouse bone marrow, at 
least in response to the thymus-dependent antigen SRBC (appendix publication 
IV). Our experiments do not allow us to select definitely between the second 
and third mechanism as the underlying cause for antibody formation in mouse 
bone marrow. Our observations that mouse bone marrow can contain I arge num-
bers of anti-SRBC (appendix publications I and IV) and anti-LPS (Benner ond 
van Oudenaren, to be published} PFC while all other lymphoid organs do not 
show any significant PFC activity argue against the third mechanism. One can 
hardly imagine that large numbers of lymphocytes are stimulated to differen-
tiate into antibody-forming cells outside the bone marrow without providing 
for any PFC response at these sites. The experiments of Ropke and Everett (81) 
mentioned above also do not favour the third mechanism. Therefore in forth-
coming experiments to elucidate the underlying cause for antibody formation in 
mouse bone marrow the second mechanism will remain our working hypothesis. 
Supposing the second mechanism indeed is the underlying cause for antibody 
formation in mouse bone marrow, the question arises as to whether there is a 
fundamental difference between the anti-LPS and anti-SRBC PFC response in 
mouse bone marrow regarding the type of lymphocytes involved, virgin cells 
or memory cells. Vvhile the results of splenectomy experiments clearly suggest 
the bone marrow anti-SRBC PFC response to be dependent on memory cells, 
one can ask oneself whether virgin B cells can provide for the anti-LPS PFC 
response in the marrow. This touches directly upon the origin of the immuno-
competent B cells in the bone marrow. Osmond and Nossal recently showed the 
mouse bone marrow to be involved in the generation of virgin B· cells (82). 
These authors studied the appearance of surface-immunoglobulins (I g) on short-
[ ived lymphocytes generated in the marrow. They provided strong evidence 
that small lymphocytes in the marrow are initially lg-negative but rapidly 
express increasing amounts of surface-lg during differentiation and proliferation. 
Basten and coworkers using a radioactively labeled antigen 1suicide 1 technique 
have shown that, in conditions in which thymocytes and spleen B cells are 
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inactivated, bone marrow lymphocytes are unaffected (83). This could be inter-
preted as suggesting that maturation to the antigen-binding stage takes place 
outside, and not within the bone marrow. Everett and Caffrey indeed provided 
evidence for a continuous transport of recently generated small lymphocytes 
from the bone marrow to the spleen (84). Therefore it is a real possibility 
that all immunocompetent B cells in mouse bone marrow, including the B cells 
specific for LPS, are immigrated long-lived memory cells for environmental 
antigens stimulating the lymphoid system. Autoradiographic studies are consis-
tent with this supposition, since in mice essentially no short-lived lymphocytes 
migrate into the bone marrow (81, 85), while long-lived B lymphocytes nor-
mally do so (81,. 86). This line of evidence led us to conclude that there is 
not: necessarily a fundamental difference between the anti-LPS and anti-SRBC 
PFC response in mouse bone marrow. 
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SUMMARY 
Lymphoid organs are generally subdivided into two groups according to 
their contribution to antibody formation: 1 primary' and 1secondary• lymphoid 
organs. In mammals bone marrow and thymus are considered to be 'primary 1 
because these organs are involved in the generation of lymphocytes: B cells 
and T cells respectively. These lymphocytes can leave their place of origin 
and provide for antibody formation in secondary lymphoid organs: spleen, 
lymph nodes, Peyer's patches and other gut-associated lymphoid tissue. 
For rabbit, guinea pig and mole rat it has been shown that antibody forma-
tion can occur not only in secondary lymphoid organs but also in the bone 
marrow. The plaque-assay, which is a direct assay to demonstrate the presence 
of antibody-forming cells, has been very little applied to the bone marrow. As 
far as this assay has been used to demonstrate antibody-forming cells in the bone 
marrow, its use has been limited almost exclusively to the bone marrow of the 
mouse. Using this assay only small numbers of antibody-forming cells have been 
found in the bone marrow of immunized mice. In striking contrast to these re-
sults we found with the same assay that mouse bone marrow can contain large 
numbers of antibody-forming cells after intravenous (i.v.) immunization with the 
thymus-dependent sheep red blood cell (SRBC) antigens and the thymus-inde-
pendent antigen Escherichia coli I ipopolysaccharide (LPS). 
In appendix publication I the primary and secondary antibody-forming cell 
(PFC) response of the mouse to i.v. iniections of SRBC was studied. 
During the primary response a great number of PFC appeared in the spleen 
while only a few PFC were found in the marrow. During the secondary re-
sponse there was a clear PFC response in both the spleen and the bone marrow. 
The spleen contained the majority of PFC during the first phase of the response. 
The bone marrow PFC response was characterized by (1) a delayed appearance 
as compared with the spleen, and (2) an up to ten times as high PFC activity 
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as in the spleen during the second phase of the response. lgM-PFC as well 
as lgG- ond lgA-PFC could be demonstrated in the morrow. In the lymph 
nodes and Peyer 1s patches the number of PFC did not increase above the 
normal background level at any time after primary or secondary immunization. 
In order to test whether the bone marrow PFC response was caused by mi-
gration of PFC from the spleen or by development in situ, mice were splenec-
tomized shortly before the second injection of SRBC. It could be shown that 
splenectomy did not prevent the bone marrow PFC response. Because no PFC 
activity in the other lymphoid organs was observed the PFC activity of the 
marrow was concluded to be result from development of antibody-forming cells 
in situ. 
The presence of a distinct anti-SRBC PFC response in mouse bone marrow 
during the secondary response might be related to the generation of memory 
cells after the first injection of the antigen. In appendix publication II this 
possibility was investigated by means of cell transfer experiments. 
T cells, which are involved in an anti-SRBC PFC response, were shown to 
be very sc6rce in normal mouse bone marrow, which is considered to be the 
cause of the low PFC activity in the marrow during the primary response to 
SRBC. 
In normal mouse bone marrow precursors of lgM-PFC but not of lgG- and 
lgA-PFC could be found. Priming with SRBC induced the appearance of lgM-, 
lgG-, lgA- and T-memory cells in the marrow. These B- and T-memory cells 
were shown to be specific for the antigen which induced their appearance. 
It was suggested in this paper that after a second injection of SRBC lgM-, 
lgG- and lgA-memory cells can differentiate with the help ofT-memory cells 
within the bone marrow into lgM-, lgG- and lgA-PFC respectively. 
In appendix pub I ication Ill the influence of the route of priming and dose 
of SRBC on the secondary bone rna rrow PFC activity was studied. 
After intraperitoneal and subcutaneous priming the number of lgM-, lgG-
and lgA-PFC in the bone marrow during the secondary response increased with 
the number of SRBC used for priming. After i.v. priming an optimal dose 
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of SRBC was found for lgM-PFC as well as for lgG- and lgA-PFC ta appear 
in mouse bone marrow during the secondary response. The peak secondary 
response in the bone morrow was found after priming with 107 and with 108 
SRBC i.v. 
The appeorance of lgM-, lgG- and lgA-memory cells in the bone marrow 
after i.v. immuniz.ation with SRBC was shown to be dependent on the priming 
dose. The appearance of lgG-memory cells required a higher dose of SRBC 
than the appearance of lgM-memory cells, and the appearance of lgA-memory 
cells required even more antigen. 
The effect of the booster dose upon the PFC activity was .studied in mice 
primed with 107 SRBC i.v. and boosted with 104, 106 or 109 SRBC i.v. 2 
months later. lgM-PFC as well as lgG- and lgA-PFC were present in spleen 
and bone marrow at each booster dose tested. In each group of mice the PFC 
activity in the bone marrow rose to a level which surpassed the level in the 
other lymphoid organs between the 7th and 10th day after the booster injection. 
Thus, independently of the booster dose, mouse bone marrow appeared to be 
the .maior source of PFC during the second phase of the secondary response 
to Lv. SRBC. 
Appendix publication IV deals with the influence of splenectomy on the bone 
marrow PFC response to SRBC. Splenectomy before priming with an optimal 
dose of 107 SRBC i.v. completely prevented bone marrow PFC activity during 
the secondary response. Cell transfer experiments revealed that splenectomy 
before priming with 107 SRBC i.v. also prevented the appearance of B- and T-
memory cells in the bone marrow. The influence of splenectomy on both appea-
rance of B- and T-memory cells and secondary bone marrow PFC activity could 
be partly overcome by priming with a higher antigen dose of 4 x 108 SRBC i.v. 
These results provided evidence that antibody formation in mouse bone marrow 
is dependent on the presence of memory cells. 
In appendix pub I ication V the occurrence of PFC in mouse bone marrow 
was studied during the primary and secondary response to various doses of LPS. 
During the primary response i.v. doses of 1 and 10 !J9 LPS were found to 
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evoke a distinct lgM-PFC response in both spleen and bone marrow. The 
spleen contained the majority of PFC until about 5 days after immunization. 
In the course of the reaction the number of PFC in the bone marrow rose to 
a level which equalled or surpassed the level in the spleen. Doses of 0.001, 
0.01 and 0.1 ~g LPS i.v. only induced a lgM-PFC response in the spleen. 
Apparently there is a minimal threshold dose of LPS of about 1 ~g for 
anti-LPS PFC to appear in the bone marrow. 
The secondary response was studied in mice primed with 1 /l9 LPS i.v. and 
boosted with either 0.001, 0.1 or 10 ~g LPS i.v. three months later. After 
each dose tested the lgM-PFC activity in the spleen was several times higher 
than during the primary response. As was observed during the primary response 
i.v. doses of 0.001 and 0.1 ~g LPS did not evoke a PFC response in the bone 
marrow. A significant lgM-PFC response after boosting with 10 flg LPS i.v. 
was found not only in spleen and bone marrow but also in thymus, lymph 
nodes, Peyer's patches and blood. From about 5 days after the booster injec-
tion the number of PFC in the bone marrow exceeded the total number found 
in all other lymphoid organs. 
In conclusion during the primary response to SRBC PFC could be barely 
demonstrated in mouse bone marrow. However, a very distinct lgM-, lgG- and 
lgA-PFC activity was present in this organ during the secondary response to 
SRBC. LPS was found to be able to evoke on lgM-PFC response in the bone 
marrow both during the primary and the secondary response. The anti-SRBC 
and anH-LPS PFC response in the bone marrow was characterized by (l) 
a delayed appearance of PFC as compared with the spleen, and (2) an up 
to ten times as high PFC activity as in all the other lymphoid organs to-
gether during the second phase of the response. In contrast to the secondary 
response to SRBC, the bone marrow reguired much more antigen than the 
spleen for onti-LPS PFC to appear. 
Non-antibody-producing cells were found to be able to differentiate within 
the bone marrow into anti-SRBC PFC. The occurrence of these anti-SRBC PFC 
in the bone marrow probably requires specific memory cells. The results of 
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splenectomy experiments suggest that secondary lymphoid organs are the site 
of origin of these memory cells. 
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SAMENVATTING 
Overeenkomstig hun bijdrage aan de antilichaamvorming worden lymfoYde 
organen in twee groepen ingedeeld: 11 primaire" en 11 secundaire 11 lymfo"lde or-
ganen. Bij zoogdieren worden beenmerg en thymus als primaire lymfo"ide or-
ganen beschouwd, omdat deze organen betrokken zijn bij de vorming van lym-
focyten: respectievelijk B-cellen en T-cellen. Deze lymfocyten kunnen de 
pleats waar ze gevormd worden verlaten en zorgen voor de vorming van anti-
lichamen in. secundaire lymfo"lde organen: milt, lymfklieren, plaques van Peyer 
en ·onder darm-geassoc ieerd I ymfo"id weefsel. 
Bij konijn, cavia en westelijke blinde muis heeft men aangetoond, dot anti-
lichaamvorming niet aileen kan plaatsvinden in secundalre lymfoTde organen, maar 
ook in het beenmerg. De plaque-test, een direkte test om de aanwezigheid van 
antilichaamvormende cellen aan te tonen, is slechts zelden toegepast op het 
beenmerg. Voor zover deze test gebruikt is om antilichaamvormende cellen in 
het beenmerg aan te tonen, is deze vrijwel uitsluitend tot het beenmerg van 
muizen beperkt gebleven. Tot dusver heeft men met deze test slechts kleine 
aantallen antilichaamvormende cellen in het beenmerg van geYmmuniseerde 
m'Jizen gevonden. Wij vonden echter met dezelfde test, dot het beenmerg van 
muizen grote aantallen antilichaamvormende eel/en kan bevatten na intraveneuze 
(i.v.) immunisatie met schape-rade-bloedcellen (SRBC), een thymus-afhankeliik 
antigeen, en lipopolysaccharide (LPS) van Escherichia coli, een thymus-onafhan-
kelijk antigeen. 
In publikatie van de appendix werden de primaire en secundaire humorale 
immunologische reaktie van de muis na i.v. injekties met SRBC bestudeerd. 
Tijdens de primaire reaktie verscheen een groot aantal antilichaamvormende 
cellen (PFC) in de milt, en slechts een klein aantal in het beenmerg. Tijdens 
de secundaire reaktie was er een duidelijke PFC-reaktie, zowel in de milt 
als in het beenmerg. De milt bevotte het grootste aontol PFC tijdens de eerste 
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fase van de reaktie. De PFC-reaktie in het beenmerg werd gekarakteriseerd 
door (1) een vertraagde verschiining vergeleken met de milt, en (2) een maxi-
mao/ tien mao/ zo grate PFC-aktiviteit als in de milt tijdens de tweede fase 
van de reaktie. Zowel lgM-PFC als lgG- en lgA-PFC konden worden aange-
toond in het beenmerg. Geen enkele maal na primaire of secundaire immuni-
satie steeg het aantal PFC in lymfkl ieren en plaques van Peyer uit boven het 
normale achtergrond-niveau. 
Om te testen of de PFC-reaktie in het beenmerg veroorzaakt werd door mi-
gratie van PFC vanuit de milt of door ontstaan in situ, werden muizen kart 
voor de tweede injektie met SRBC gesplenectomeerd (d.w.z. hun milt werd 
operatief verwijderd). Er kon worden aangetoond, dat splenectomie de PFC-
reaktie in het beenmerg niet verhinderde. Omdat geen PFC-reaktie in de 
andere lymforde organen werd waargenomen, _werd geconcludeerd dot de PFC-
reaktie in het beenmerg veroorzaakt wordt door het ontstaan van antilichaam-
vormende cellen in situ. 
De aanwezigheid van een duidelijke anti-SRBC PFC-reaktie in het been-
merg van de muis tijdens de seeundaire reaktie zou verband kunnen houden 
met de vorming van memory-eel/en na de eerste antigeen-injektie. In publi-
katie II van de appendix werd deze mogelijkheid onderzocht door middel 
van ee ltransfer-experimenten. 
T-ee/len, die betrokken zijn bij een anti-SRBC PFC-reaktie, bleken zeer 
schaars in het beenmerg van normale muizen. Dit wordt beschouwd als de 
oorzaak van de loge PFC-aktiviteit in het beenmerg tijdens de primaire reck-
tie tegen SRBC. 
In het beenmerg van normale muizen konden wei lgM-B-eellen, maar geen 
lgG- en /gA-B-eel/en voor SRBC worden aangetoond. Priming (d.w.z. de 
eerste immunisatie) met SRBC induceerde de verschijning van lgM-, lgG-, 
lgA- en T -memory-eel/en in het beenmerg. Er werd aangetoond dot deze 
B- en T-memory-eellen specifiek waren voor het antigeen dat hun versehijning 
indueeerde. In deze publikatie werd gesuggereerd dot na een tweede injektie 
met SRBC lgM-, lgG- en lgA-memory-cellen met behulp van T-memory-cellen 
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in het beenmerg kunnen differentieren tot respectievelijk lgM-, lgG- en 
lgA-PFC. 
In pub I ikatie Ill van de appendix werd de invloed van de wqze van priming 
en de dosis SRBC op de secundaire PFC-reaktie in het beenmerg bestudeerd. 
Na intraperitoneale en subcutane priming nam het aantal lgM-, lgG- en 
lgA-PFC in het beenmerg tijdens de secundaire reaktie toe met het aantal 
SRBC dat gebruikt was 'vOOr priming. Bij i.v. priming werd er een optimale dosis 
SRBC gevonden voor secundaire lgM-, lgG- en lgA-PFC-aktiviteit in het 
beenmerg. De sterkste secundaire reaktie in het beenmerg werd verkregen na 
i.v. priming met 1l en met 108 SRBC. 
De verschijning van lgM-, lgG- en lgA-memory-cellen in het beenmerg na 
i.v.· immunisatie met SRBC bleek afhrnkelijk van de gebruikte dosis. De ver-
schijning van lgG-memory-cellen vereiste een hogere dosis SRBC dan de ver-
schijning van lgM-memory-cellen, en voor de verschijning van lgA-memory-
cellen was nog meer antigeen nodig. 
De invloed van de dosis SRBC gebruikt voor tweede immunisatie werd be-
studeerd in muizen die i.v. geprimed waren met 10
7 
SRBC en 2 maanden daar-
na i.v. geboosterd (d.w.z. voor de tweede maal ge"immuniseerd) waren met 
4 6 9 10 , 10 of 10 SRBC. Na elk van deze booster-doses waren er lgM-, lgG-
en lgA-PFC aanwezig in milt en beenmerg. In elke groep muizen steeg het 
aantal PFC in het beenmerg tussen de zevende en tiende dog na de tweede 
immunisatie uit boven het totale aantal in de andere lymfoTde organen samen. 
Blijkbaar is het beenmerg van de muis, onafhankelijk van de booster-dosis, 
de belangrijkste bron van PFC tijdens de tweede fase van de secundaire 
reaktie tegen SRBC i.v. 
Publikatie IV van de appendix handelt over de invloed van splenectomie op 
de PFC-reaktie tegen SRBC in het beenmerg. Splenectomie voor i.v. priming 
met een optimale dosis van 107 SRBC verhinderde de verschijning van PFC in 
het beenmerg tijdens de secundaire reaktie. Celtransfer-experimenten toonden aan 
dat splenectomie voor i.v. priming met 107 SRBC tevens de verschijning van 
B- en T -memory-cell en in het beenmerg voorkwdm. Deze invloed van splenec-
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tomie op de verschijning van B- en T-memory-cellen en secundaire PFC-
aktiviteit in het beenmerg kon gedeeltelijk teniet gedaan worden door i.v. 
te primen met een hogere antigeen-dosis, en wei met 4 x 108 SRBC. Deze 
resultaten 9aven aanwijzingen, dot antilichaamvorming in het beenmerg van 
muizen afhankelijk is van de aanwezigheid van memory-cellen. 
1n publikatie V van de appendix werd het v66rkomen van PFC in het been-
merg van muizen tijdens de primaire en secundaire reaktie op verschillende 
doses LPS bestudeerd. 
Tijdens de primaire reaktie bleken i.v. doses van 1 en 10 pg LPS een dui-
delijke lgM-PFC-reaktie in zowel milt als beenmerg op te wekken. De milt 
bevatte het grootste aantal PFC tot ongeveer 5 dagen na immunisatie. In de 
loop van de reaktie steeg het aantal PFC in het beenmerg tot een niveau 
dot het aantal in de milt evenaarde of overschreed. LPS-doses of 0,001, 
0,01 en 0,1 pg i.v. induceerden aileen een lgM-PFC-reaktie in de milt. 
Blijkbaar is er een minimum-dosis LPS van ongeveer 1 J-!9 die bereikt moet 
worden voordat anti-LPS PFC in het beenmerg verschijnen. 
De secundaire reaktie werd bestudeerd in muizen die i.v. geprimed waren 
met l J-!9 LPS en drie maanden later i.v. geboosterd waren met 0,001, 0,1 of 
10 pg LPS. Na elke dosis die getest werd, was de lgM-PFC-aktiviteit in de 
milt enige malen groter dan tijdens de primaire reaktie. Evenals tijdens de 
primaire reaktie waren doses van 0,001 en 0,1 pg LPS i.v. niet in stoat een 
PFC-reaktie in het beenmerg op te wekken. Na i.v. boosteren met 10 pg LPS 
was er niet aileen in milt en beenmerg, maar ook in thymus, lymfkl ieren, 
plaques van Peyer en bloed een significante lgM-PFC-reaktie. Vanaf ongeveer 
5 dagen no de booster-injektie was het aantal PFC in het beenmerg groter 
dan het totale aantal in aile andere lymfo'lde organen samen. 
Bovenstaande resultaten kunnen als volgt samengevat worden. Tijdens de 
primaire reaktie tegen SRBC konden PFC nauwelijks worden aangetoond in het 
beenmerg van de muis. Er was echter een zeer duidelijke aktiviteit van lgM-, 
lgG- en lgA-PFC tijdens de secundaire reaktie tegen SRBC. LPS bleek zowel 
tijdens de primaire als tijdens de secundaire reaktie in stoat een lgM-PFC-reak-
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tie in het beenmerg op te wekken. De anti-SRBC en anti-LPS PFC-reakties 
in het beenmerg werden gekenmerkt door (l) een vertraagde verschijning van 
PFC. vergeleken met de milt, en (2) een maximaal tien maal zo grote PFC-akti-
viteit als in aile andere lymfo"ide organen samen tijdens de tweede fase van 
de reaktie. In tegenstelling tot de secundaire reak-tie tegen SRBC was voor een 
anti-LPS PFC-reaktie in het beenmerg een hogere antigeen-dosis nodig dan 
voor een anti-LPS PFC-reaktie in de milt. 
Er werden aanwijzingen verkregen, dat cellen die geen antilichamen produ-
ceren, in het beenmerg kunnen differentH:;ren tot anti-SRBC PFC. Waarschijnlijk 
zijn voor een anti-SRBC PFC-reaktie in het beenmerg specifieke memory-cellen 
nodig. De resultaten van splenectomie-experimenten duiden erop, dot deze me-
mory-cellen worden gevormd in secundaire lymfoTde organen. 
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Antibody Formation m Mouse Bone Marrow 
I. EVIDENCE FOR THE DEVELOPMENT OF PLAQUE-FORMING CELLS 
IN SITU 
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Department of Cell Biology and Genetics, Erasmus University, P.O. Box 1738 
Rotterdam, The Netherlands 
(Received 4th June 1973; accepted for publication 20th July 1973) 
Summary. Mouse bone marrow as a source of plaque-forming cells (PFC) was 
studied by single and multiple intravenous injections of sheep erythrocytes (SRBC). 
In the primary response a great number of PFC appeared in the spleen while only 
a few showed up in the marrow. In the secondary response there is a clear PFC-
response in both the spleen and the bone marrow. The spleen contains the majority 
of PFC until about 9 days after the second injection. In the course of the reaction, 
however, the number of PFC in the bone marrow rises to a level which surpasses 
the level in the spleen. IgM-PFC as well as IgG-PFC and IgA-PFC could be 
demonstrated in the marrow. In the lymph nodes and Peyer's patches the number 
of PFC did not increase above the normal background level at any time after the 
primary or secondary immunization. In order to test whether the bone marrow 
PFC-response is caused by a migration of PFC from the spleen or by development 
in situ, mice were splenectomized shortly before the second injection of SRBC. 
It could be shown that splenectomy does not prevent the bone marrow PFC-
response. Because no activity in the other lymphoid organs was observed, it is 
concluded that the PFC activity of the marrow is caused by development in situ. 
INTRODUCTION 
Antibody- and y-globulin synthesis can take place in bone marrow. In the early part 
of the century it was stated that the bone marrow of immunized guinea-pigs (Ludke, 
1912) and rabbits (Ludke, 1912; Reiter, 1913) is capable of antibody-production in 
vitro. In recent years antibody- andy-globulin synthesis in the bone marrow were reported 
for guinea-pig (Askonas and White, 1956; Askonas, White and Wilkinson, 1965; Fleming, 
Wilkinson and White, 1967), rabbit (Thorbecke and Keuning, 1953, 1956; Askonas and 
Humphrey, 1958; Thorbecke, 1960; Thorbecke, Asofsky, Hochwald and Siskind, 1962), 
human (Asofsky and Thorbecke, 1961; van Furth, 1966; McMillan, Longmire, Yele-
nosky, Lang, Heath and Craddock, 1972) and monkey (Asofsky and Thorbecke, 1961) 
bone marrow in vitro. 
Studies in rabbits (Kolouch, Good and Campbell, 1947) and in man (Good, 1955) 
provided evidence for a positive correlation between the plasma cell content of the bone 
marrow and the serum titre after intensive antigenic stimulation. Recently Hijmans, 
Schuit and Hulsing-Hesselink (1971) and Silverman, Yagi, Pressman, Ellison and 
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Tormey (1973) reported studies of human bone marrow cells analysed for the presence 
of immunoglobulins with the fluorescent antibody technique. The K/A ratio and the per-
centage distribution of cells of the lymphoid series which were positive for the heavy 
chains of the major classes (,, f1 andy) showed a striking similarity with the K/A ratio 
in the serum and with the percentage distribution of the serum immunoglobulins, if 
corrected for pool size and metabolic rate. Hijmans and Schuit (1972) concluded that in 
humans bone marrow is a major source of immunoglobulins. 
So far mouse bone marrow has not been demonstrated to contain a substantial number 
of plaque-forming cells (PFC) after immunization (Friedman, 1964; Eidinger and Pross, 
1967; Chaperon, Selner and Claman, 1968; Mellbye, 1971; Cohen, 1972; Anderson and 
Dresser, 1972). However, some activity in the bone marrow was found with an increasing 
interval after immunization with sheep red cells (SRBC) (Eidinger and Pross, 1967; 
Chaperon eta!., 1968; Mellbye, 1971; Anderson and Dresser, 1972). 
We have studied the primary and secondary response against SRBC by the haemolytic 
plaque assay in mouse bone marrow. The activity of the marrow was compared with the 
activity of the other lymphoid organs. We have shown that after two intravenous injec-
tions with SRBC, mouse bone marrow contains a considerable part of the total number 
of PFC. The presence of these large numbers of PFC in bone marrow may be due to a 
migration of PFC from the spleen. Such transport is suggested in the literature (Lange-
voort, Asofsky,Jacobsen, de Vries and Thorbecke, 1963, van Furth et al., 1966; Chaperon 
et al., 1968; Hijmans and Schuit, 1972). We tested this possibility by studying the second-
ary response of bone marrow in mice, splenectomized shortly before their second injection 
of SRBC. 
MATERIALS AND METHODS 
Mice 
(C57BlfRij x CBA/Rij) F 1 female mice, 20 weeks old were used. They were purchased 
from the Medical Biological Laboratory (Rijswijk, The Netherlands). 
Immunization 
For primary immunization, the mice received an intravenous injection of 4 x 108 
SRBC. This injection was repeated in 5 weeks for the secondary immunization. 
Splenectomy 
Spenectomy and sham-splenectomy were performed 1 day before the second injection 
of SRBC. The mice were anaesthetized with an intraperitoneal injection of 70 mgfkg 
body weight Nembutal (Abbott S. A., Saint-Remy-sur-Avre, France). There was no 
post-operative mortality. 
Preparation of cell suspensions 
At various times following immunization four or five animals were killed. Immediately 
after killing the mice with ether, the spleens, femurs, peripheral lymph nodes (inguinal, 
brachial and axillary), mesenteric lymph nodes and Peyer's patches were removed and 
brought into a balanced salt solution (BSS). This solution was prepared according to 
Mishelland Dutton (1967) and was always supplemented with5 percentnewborncalfserum. 
Bone marrow was obtained by flushing the femurs with BSS. Spleens, lymph nodes, 
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Peyer's patches and bone marrow were minced with sc1ssors and squeezed through a 
nylon-gauze filter to give a single cell suspension. 
Assay for PFC 
The method for detection of PFC developed by Cunningham and Szenberg (1968) 
was adopted with some modifications as described by Zaalberg, van der Meul and 
Twisk (1968). One coverslip of60 x 24 mm was used per microscope slide. The maximum 
concentration of cell suspension was 2 x 107 cellsjml and a volume of 0·4 ml was used for 
each test. The chambers were incubated at 37' for 2 hours. The number of IgM-PFC 
was calculated from a direct assay in which the slides were developed with guinea-pig 
complement (Flow Laboratories, Rockville, U.S.A.) only. The number of IgM-PFC+ 
IgG-PFC was calculated from an indirect assay in which the slides were developed with 
guinea-pig complement and rabbit-anti-mouse-IgG. The number of IgG-PFC was ob-
tained by subtracting the number of PFC obtained in the direct assay from those obtained 
in the indirect assay. The number of IgA-PFC was calculated in a similar way employing 
rabbit-anti-mouse-IgA. From the results of the femoral bone marrow the number of PFC 
present in the marrow of the whole animal was estimated, using the data of Chervenick, 
Boggs, March, Cartwright and Wintrobe (1968), who showed that in mice one femur con-
tains 5·9 per cent of the marrow. 
Hyperimmune serum 
For hyperimmune-anti-SRBC serum (C57Bl/Rij x CBA/Rij) F 1 female mice received 
four injections of 4 x 108 SRBC. The first injection was given intravenously, and 
subsequent ones were administered every other week intraperitoneally. The agglutination 
titre of the serum used was I: 2 16 • 
Statistics 
The standard deviation (S.D.) associated with p plaques counted was calculated as 
the square root of P+0·004 x p 2 This formula was drawn up by ]erne for the agar plaque 
assay. For calculation of the 95 per cent confidence limits the formula P+ two S.D. was 
used. The presence of IgG and IgA was accepted as significant when there was no overlap 
between the upper limit in the direct assay and the lower limit in the indirect assay. 
RESULTS 
PRIMARY RESPONSE 
After a single i.v. injection of 4 x I 08 SRBC the main PFC-activity could be observed 
in the spleen (Fig. 1). Only slight activity was detected in the bone marrow; during the 
early response some IgM-PFC appeared, but were not detected in significant quantities. 
However, after 27 days small numbers of IgM-, IgG- and IgA-PFC could be found in 
the marrow. In the peripheral lymph nodes, the mesenteric lymph node, and Peyer's 
patches the presence of PFC above the normal background level could not be demon-
strated. 
SECONDARY RESPONSE 
A second i.v. i~ection of 4x 108 SRBC, given 5 weeks after the first one, resulted in 
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( •) Spleen and (e) bone marrow. Where ( •) is added to an experimental point it means that the 
number of IgG-PFC or IgA-PFC above the level of IgM-PFC was not significant. 
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the rapid appearance of IgM-, IgG- and IgA-PFC in the spleen as well as in the bone 
marrow (Fig. 2). During the first 9-10 days the spleen contained the majority of the PFC; 
however, in the course of the reaction the bone marrow became more important as a 
source of PFC. After the 9th day the bone marrow contained as many IgM-, IgG- and 
IgA-PFC as the spleen. After the 13th day IgG-PFC in the bone marrow were even more 
numerous. The number of PFC in peripheral lymph nodes, mesenteric lymph node and 
Peyer's patches remained at the normal background level. 
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FIG. 3. Number of PFC in mouse bone marrow after two i.v. injections of 4 x 108 SRBC. The second 
injection was given 5 weeks after the first. ( •) Sham-splenectomy and (e) splenectomy. Sham-
splenectomy and splenectomy were performed I day before the second injection ofSRBC. Where (.6.) 
is added to an experimental point it means that the number of lgG-PFC or IgA-PFC above the level of 
IgM-PFC was not significant. 
SECONDARY RESPONSE OF BONE MARROW AFTER SPLENECTOMY 
In the literature it has been suggested that PFC can migrate from spleen to bone 
marrow (Langevoort et al., 1963; van Furth et al., 1966; Chaperon, et al., 1968; Hijmans 
and Schuit, 1972). To find out whether or not this migration causes the activity of the 
bone marrow during secondary response in our system, an experiment was performed in 
which mice were splenectomized I day before the second intravenous injection of SRBC. 
Fig. 3 shows that splenectomy is not able to prevent the activity of the bone marrow 
in the secondary response. Once again, peripheral lymph nodes, mesenteric lymph node 
and Peyer's patches did not show an increase of the number of PFC. Therefore the PFC 
activity in bone marrow appears to be caused by a development of PFC in situ. 
It is noteworthy that the bone marrow of the splenectomized animals as compared 
with the sham-splenectomized ones demonstrates an even higher PFC activity. Two ex-
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FIG. 4. Number of PFC in mouse bone marrow 6 days after the last of two i.v. injections of4 x 108 
SRBC. The second injection was given 5 weeks after the first. Open columns, sham-splenectomy; 
cross-hatched columns, splenectomy; hatched columns, splenectomy plus an i.v. injection of 0·5 ml 
hyperimmune anti-SRBC-serum. Operations were performed 1 day before the second injection of 
SRBC. The serum was administered 2 days after the second antigen injection. 
planations for this phenomenon can be postulated. One explanation includes the absence 
of suppressing antibodies from the spleen. A regulatory effect of antibodies on the PFC 
response has been described (Uhr and Moller, 1968). This possibility was tested by giving 
splenectomized mice an intravenous injection of 0·5 ml hyperimmune anti-SRBC-
serum on the second day after the second antigen administration. The titre observed in 
normal mice injected with this amount of anti-SRBC-serum was 214• Fig. 4 shows that 
the administration of hyperimmune anti-SRBC-serum suppressed the bone marrow 
PFC response. Another explanation could be that in the absence of the spleen more 
antigen is taken up by the bone marrow. The influence of the antigen supply on the bone 
marrow PFC activity was studied by challenging two groups of intact mice with doses of 
4 x l 08 and l 09 SRBC respectively. As shown in Fig. 5 an increased amount of SRBC 
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Fro. 5. Number ofPFC in mouse bone marrow after two i.v. injections of SRBC. Both groups received 
a first injection of 4 x 108 SRBC. One group (e) received a second injection of 109 SRBC; the other 
group (0) was inoculated with 4x 108 SRBC. 
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stimulated the bone marrow to a somewhat greater activity. It is questionable whether 
this greater activity of the bone marrow is a direct consequence of this increased antigen 
supply. It is possible that the larger amount of SRBC reduces the concentration of free 
circulating anti-SRBC-antibodies from the primary response, thereby diminishing the 
negative feed back of these antibodies upon the secondary response of the marrow. 
DISCUSSION 
The bone marrow is generally considered to be a primary lymphoid organ, since among 
its progeny are lymphocytes which are of major importance for the immunological 
capacity of other lymphoid organs (Miller, 1968). In vitro experiments (Thorbecke and 
Keuning, 1953, 1956; Askonas and Humphrey, 1958; Askonas and White, 1956; Lange-
voort et al., 1963; Askonas et al., 1965; Fleming et al., 1967) demonstrate that bone marrow 
itself is capable of antibody synthesis. In these experiments the authors used bone marrow 
of primed organisms. Bone marrow of unprjmed organisms is unable to respond to anti-
genic stimulation in vitro (Thorbecke and Keuning, 1956; Langevoort et al., 1963; Mc-
Millan et al., 1972). 
Calculations of the contribution of the bone marrow to the overall production of 
immunoglobulins suggest that the marrow may be a major source of immunoglobulins 
(Askonas and White, 1956; Hijmans and Schuit, 1972; McMillan et al., 1972). 
Experiments in which the activity of the bone marrow was tested with the haemolytic 
plaque assay have been reported, with mice used as experimental animals (Friedman, 
1964; Bidinger and Pross, 1967; Chaperon et al., 1968; Mellbye, 1971; Cohen, 1972; 
Anderson and Dresser, 1972). Calculation of the total amount of PFC in mouse bone 
marrow requires an estimation of the number of bone marrow cells in the entire animal. 
For our calculations we made use of the results of Chervenick et al. (1968). These authors 
demonstrated with 59Fe-labelling that one femur of a mouse contains 5·9 per cent of its 
bone marrow. Although the distribution of 59Fe is not necessarily representative for the 
distribution of lymphocytes, it gives a clue for the total amount of bone marrow. Using 
this estimation we found a small number of PFC in the bone marrow during the late 
phase of the primary response after intravenous immunization (Fig. I). This observation 
is consistent with the results of others (Bidinger and Pross, 1967; Chaperon et al., 1968; 
Mellbye, 1971; Anderson and Dresser, 1972) using other routes of immunization. How-
ever, during the secondary response the bone marrow is particularly active, even in the early 
phase (Fig. 2). In a comparable experimental approach Bidinger and Pross (1967) found a 
small number of IgG-PFC in the bone marrow during the early response after a second 
intradermal immunization. 
It is worth noting that the bone marrow needs a longer period of induction than the 
spleen. It was also demonstrated in rabbits that non-splenic sites have a longer lag time 
than the spleen after intravenous injections of SRBC (Taliaferro and Taliaferro, 1952). 
The spleen appears to synthesize antibody more rapidly after intravenous injections of 
SRBC than the bone marrow. 
From the 9th to the 13th day the bonemarrowcontainsapproximatelyasmany IgM-, IgG-
and IgA-PFC as the spleen. From the 13th day on the major part of the total number ofigG-
PFC is found in the bone marrow. This strong IgG-PFC activity corresponds well with 
the other results published (van Furth et al., 1966; McMillan, 1972). It has been sug-
gested in the literature (Langevoort et al., 1963; van Furth et al., 1966; Chaperon et al., 1968; 
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Hijmans and Schuit, 1972) that antibody-forming cells from the peripheral lymphoid 
organs home to the bone marrow. Because only spleen and bone marrow showed a PFC 
activity during the secondary response in our experiments we could test this suggestion 
by splenectomy before the second injection of SRBC. 
It was demonstrated that splenectomy does not prevent the secondary response of the 
bone marrow. Probably the bone marrow PFC originate in situ, because after splenec-
tomy the mesenteric lymph node, the peripheral lymph nodes and Peyer's patches did 
not show a PFC-response. 
The question then arises as to why the bone marrow is barely capable of antibody 
synthesis in the primary response, whereas a PFC activity in the secondary response can be 
clearly demonstrated. The most plausible explanation is that memory cells appear in the 
bone marrow after antigenic stimulation, so that a subsequent dose of the antigen triggers 
the development of B memory-cells into PFC. Experiments confirming this explanation 
will be described in a following paper. Finally it is interesting that the bone marrow com-
pensates for the loss of the spleen by a greater number of PFC in comparison with the 
sham-splenectomized animals. The absence of regulating antibodies from the spleen (Fig. 4) 
is probably the cause of this greater activity of the bone marrow. 
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II. Evidence for a Memory-Dependent Phenomenon 1 
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Yfouse bone marrmv is barely capable of plaque-forming cell (PFC) activity in a 
primary response to sheep red blood cells (SRBC), \vhile PFC activity in the second-
ary response to SRBC can be clearly demonstrated. This phenomenon \vas studied 
by means of cell transfer experiments. 
T cells, \>.'hich are involved in an anti-SRBC PFC response, were shown to be very 
scarce in normal mouse bone marro\v, This is considered to be the cause of the lo\v 
PFC activity in the marrow during the primary response to SRBC. 
In normal mouse bone marrow precursors of Ig1·1-PFC but not of IgG- and lgA-
PFC could be found .. Priming with SRBC induced the appearance of lgYf-, IgG-, 
IgA- and T -memory cells in the marrow. These B- and T -memory cells were shovm 
to be specific for the antigen which induced their appearance. It is thought that after 
a second injection of SR·BC the IgM-, IgG- and IgA-memory cells can differen-
tiate with the help of the T -memory cells within the bone marr.ow into Ig:....f-, 
IgG- and IgA-PFC respectively. 
The sequence of appearance of the B-memory cells in the bone marrow was shown 
to be Ig~f-IgG-IgA. 
Six months after the intravenous injection of SRBC, the presence of B-memory 
cells could be demonstrated not only in spleen and bone marrow, but also in peri-
pheral lymph nodes, mesenteric lymph node, Peyer's patches, thymus and blood. 
The increase in amount of B-memory cells \vas most prominent in the spleen. 
INTRODUCTION 
In a previous paper ( 1) it \vas sho\vn that mouse bone marrow is able to produce 
plaque-forming cells (PFC) in response to intravenous (iv) injection of sheep red 
blood cells (SRBC). During the primary response only a few PFC appeared in the 
marrow. However, in the course of a secondary response the number of PFC in 
the bone marrO\v rose to a level which surpassed the level in the spleen. Evidence 
\Vas presented that this response was caused by a development of PFC in situ. 
Transfer experiments reported in the literature (2-5) show that bone marrow 
cells of nonimmune mice are not able to induce antibody production against SRBC 
in an irradiated recipient. Ho\vever, in cooperation \vith thymocytes a PFC response 
against SRBC can be obtained (3-5). Apparently the bone marrow contains the ap-
propriate B cells, but the necessary T cells are absent. Immunization of the donors 
evokes an increased number of these B cells which are immunologically specific ( 6, 
~This investigation was supported by the Netherlands Foundation for Medical Research 
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7). Other publications report antibody production in irradiated recipients grafted 
with bone marrow of immunized animals (2, 5, 8, 9). Such observations suggest 
that the marrow of these donors contained T cells too. 
I n the present paper transfer experiments are described \ovhich were performed 
to investigate why the bone marrow contains a considerable number of PFC in the 
secondary response, whereas it is hardly capable of producing PFC in the primary 
response against SRBC. The results suggest that the presence of specific B- and 
T -memory cells in t he bone marrow is required before a PFC response against 
SRBC can be initiated in this organ. 
MATERIALS AND METHODS 
Mice. (C57 BL/Rij X CBAJRij) F 1 female mice, 16-20 weeks old were used. 
T hey were purchased from the ::\1edical Biological Laboratory, R ij swijk, The 
Netherlands. 
Antigen. Sheep red blood cells were obtained from the Department of Clinical 
Microbiology of the Erasmus U niversity, Rotterdam, T he Nether lands. Horse red 
blood cells (HRBC) were purchased from the National Institute of Public H ealth, 
Bilthoven, The Netherlands. 
Immunization. Donor mice were primed with one iv injection of 4 X 105 SRBC. 
In one experiment this injection was repeated five weeks later. 
Prepara-tion of cell suspensions. Cell suspensions were prepared in a balanced 
salt solution (BSS) ( 10) as described previously (1). Bone marrow was collected 
from femora and tibiae. Blood was obtained by cardiac puncture and immediately 
heparinized ( 5 U /ml). Thymocytes were collected 30 min after an intraperitoneal 
(ip) injection of the donor s with 0.05 ml of a 10% solution of carbochrome ink 
(Gurr LTD, High Wycombe, Bucks, England ) in BSS. T his facilitated differentia-
tion between thymus and adherent lymph nodes in order to avoid contamination 
of the thymocyte suspension. 
Preparation and standardization of anti-theta serum. Anti-theta serum was pre-
pared by injecting H-2 compatible AKR/FuRdA mice (bred in our own colony) 
with C3H f/ A (purchased from the Laboratory Animals Centre of the Erasmus 
University, Rotterdam, The Netherlands) thymocytes according to Reif and Allen 
( 11) . Cytotoxicity tests and cell transfer experiments indicated that the serum 
in combination with guinea pig complement (C) was cytotoxic to thymocytes, 
but not to spleen cells of thymectomized, irradiated and bone marrow reconstituted 
mice. The serum was standardized on cortisone-resistant thymocytes (Van Muis-
winkel, Van Beek and Van Soest, unpublished). These cells were obtained from 
mice who had received 2 days earlier an ip injection of 30 mg Dexamethasone so-
dium phosphate (Merck & Co., Rathway, U.S.A.) per kg body weight. One unit of 
antitheta serum was t he amount necessary to kill 96% of 10° cortisone-resistant 
thymocytes in the presence of 0.01 ml guinea pig complement. 
Antiserum t?'eatment of bone marrow cells. Bone marrow cells were treated for 
half an hour in melting ice with either anti-theta serum or normal serum from 
AKRjFuRdA mice (NMS). Three units anti-theta serum per lOG bone marrow 
cells were used. After the incubation the cells were centrifuged and resuspended 
in BSS and 0.01 ml complement, which was adsorbed previously with mouse 
spleen cells, was used per lOG cells. The cells were incubated for 15 min at 37°C, 
washed three times and resuspended in BSS. 
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Cell counts. Viable cells were counted in an haernocytometer using 0.2o/o trypan 
blue in BSS as diluent. 
Irradiation. The recipient mice received 850 rad whole body irradiation gen-
erated in a Philips Mtiller MG 300 Xray machine. Animals were irradiated in 
\vell-aerated circular Perspex cages. Physical constants of the irradiation \vere: 
250 kV (constant potential); 11 mA; added filtration of 1.0 mm Cu; irradiation 
was corrected for field inhomogeneity; focus object distance 53 cm; animals were 
irradiated at a dose rate of 30-35 radjmin. lVIaximal backscatter was achieved by 
placing the cage on a layer of 11 em hardboard. During irradiation the dose was 
measured with a Baldwin Ionex dosimeter. Radiation control mice died in 9-16 
days. 
Cell transfer. Recipients were injected iv with the appropriate cell suspension 
and either 5 X 10' SRBC or 5 X 10' HRBC within 4 hr after irradiation. Recipi-
ents inoculated with blood received the thymocytes and SRB C 1 hr after the in-
jection of the blood. On the fourth day all mice were challenged \vith either 5 X 108 
SRBC or 5 X 10' HRBC ip. Each group consisted of 5 mice. 
Assay for PFC. IgM-, IgG- and IgA-PFC in the spleen of the recipient mice 
were determined 7 days after cell transfer as described previously ( 1). The com-
plement used was adsorbed previously ·with mouse spleen cells and the appropriate 
red blood cells. 
Statistics. Calculation of the 95% confidence limits associated \vith the number 
of plaques counted \Vas done as described in our previous paper ( 1). The presence 
of IgG- and IgA-PFC vvas accepted as significant \vhen there \:vas no overlap be-
tween the upper limit in the direct assay and the 10\ver limit in the indirect assay. 
RESULTS 
Appearance of B-and T-Nle1tWr'y Cells in the Bone Nlarro·w 
Seven days after transfer of 2 X 10' Nl\1S-treated bone marrow cells of non-
immune mice into lethally irradiated recipients (Group B in Fig. 1) a maximum 
of only 300 Igl\tl-PFC could be detected in the recipient spleen. However, in com-
bination with 5 X 107 virgin thymocytes 2 X 107 Nl\IS-treated normal bone mar-
row cells (Group C in Fig. 1) evoked 18,130 IgM-PFC in the recipient spleen. 
This finding indicates that in the response against SRBC the T-cell is the limiting 
factor in mouse bone marrmv. Significant numbers of IgG- and IgA-PFC could 
not be demonstrated after transfer of normal bone marrow alone or in combination 
\vith thymocytes. Immunization of the donor mice \vith 4 X 108 SRBC, increased 
the capacity of the marrmv to cause an anti-SRBC PFC response in the spleen 
of irradiated recipient mice (Fig. 2). After priming Nl\fS-treated bone marrow 
cells Yvere capable of evoking an Igl\I-, as well as an IgG- and IgA-PFC response 
in the recipient spleen beyond the third \\reek, indicating that B-memory cells ap-
peared in the marro\v. Addition of 5 X 10' virgin thymocytes (Group C in Fig. 1) 
enhanced the response up to t\.vo times, \vhereas prior treatment of the marrow 
cells with anti-theta serum and complement (Group A in Fig. 1) reduced the 
response to about 5%. These results indicate that these B.-memory cells are 
thymus-dependent and that T -memory cells must be present at 3 \Veeks after 
priming in the marrmv of immunized mice. About 14 weeks after priming the 
amount of memory cells in the marrovv reached a plateau. 
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FIG. 1. Scheme o£ the experimental set-up used to determine the presence of B an(l T cells 
in the bone marrow before and various times after an iv injection of 4 X lOs SRBC. 
In order to determine whether or not the B- and T -memory cells in the bone 
marrow are specific for the priming antigen, bone marrovv cells of donors primed 
5 weeks before with 4 x 10e SRBC, were transferred into lethally irradiated 
recipients. Before transfer one part of the bone marrow suspension \:vas treated 
vvith anti-theta serum and complement in v·itro, and the other part with NlVlS and 
complement in vitro. As it appears in Table 1, 2 X 107 NMS-treated bone marrow 
cells of mice primed with SRBC evoked an increased number of PFC against 
SRBC but not to HRBC. So the T-memory cells are specific for the priming anti-
gen. NeviS-treated bone marrow cells (2 X 10') of SRBC-primed mice in com-
bination \Vith 5 X 107 thymocytes did not evoke increased numbers of PFC 
against HRBC as compared with 2 X 107 NNIS-treated bone marrov1r cells of non-
immune mice in combination with 5 X 107 thymocytes. Thus the Igl..II-, IgG- and 
IgA-memory cells are also specific for the antigen \vhich induced them. 
The sequence of the appearance of the B-memory cells of the main classes of 
immunoglobulins in the bone marrow \Vas studied in another experiment. At 
various times after priming of the donor mice 2 X 107 bone marrow cells were 
combined with 5 X 107 virgin thymocytes and 5 X 108 SRBC and transferred into 
irradiated recipients. From the 7th clay after priming of the donor mice the bone 
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FIG. 2. PFC responses of the spleens of lethally irradiated mice receiving 2 X 101 bone mar-
row cells from donors primed iv \vith 4 X 108 SRBC various times before cell transfer. The 
responses are given of mice receiving bone marrov>' cells pretreated \\1ith anti-theta serum 
(•), pretreated with N~IS (0), and NMS-pretreated bone marrow cells combined with 
5 X lOj virgin thymocytes (e). Addition of (.A.) to a square means that the number of PFC 
in the indirect assay did not differ significantly from the number of PFC in the direct assay. 
At the beginning of the experiment the bone marrow cells in combination with thymocytes 
could not evoke significant numbers of IgG- and IgA-PFC. Each point is a mean value ob-
tained from 5 mice. 
marrow cells evoked increased numbers of IgJ\1-PFC in the spleen of the recipient 
mice (Fig. 3). In the recipient spleen significant numbers of IgG-PFC could be 
detected at the 14th day and significant numbers of IgA-PFC could be detected 
at the 21st day after priming of the donor mice. Thus the sequence in appearance 
of B-memory cells in the bone marrmv is IglVI - IgG- IgA. 
Treatment in 'IYitro 
Anti-theta + C 
NMS+C 
NMS +C 
Anti-theta + C 
NMS+C 
NMS +C 
TABLE 1 
l\NTJ-SRBC AND ANTI-HRBC PFC RESPONSE TN THE SPLEEN OF RECIPIENT MICE INOCULATED WITH BONE 
MARROW CELLS IN COMBINATION VVITll SRBC AND HRBC RESPECTIVELY 
Thymus Cells Anti-SRBC PFC/splecna Anti-HRBC PFC/splecn" 
lglVI lgG lgA IglVI lgG lgA 
Marrow Donors Nonimmune 
- 275 80 (n.s.)l' 160 (n.s.) 270 25 (n.s.) 0 (n.s.} 
- 975 400 (n.s.) 100 (n.s.) 2,675 0 (n.s.) 250 (n.s.) 
5 X 107 33,400 5,600 (n.s.) 6,600 (n.s.) 31,600 9,600 (n.s.) 0 (n.s.) 
Marrow Donors Immunized \Vith 4 X 108 SRBC iv 
- 1,200 1,325 875 (n.s.) 120 25 (n.s.) 10 (n.s.) 
- 52,000 74,500 25,500 2,425 600 (n.s.) 1,400 (n.s.) 
5 X 10' 63,500 95,500 27,250 25,300 1,150 (n.s.) 2,200 (n.s.) 
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a Each recipient mouse received 2 X 107 viable nucleated bone marrow cells after treatment with either anti-theta serum and complement or NMS and com· Z 
plcment in vitro. Each group consisted of 5 recipient mice. PFC-assay was done on pooled spleens 7 days after cell transfer, 
b There was no significant difference between the number of PFC in the direct assay and the l11Jmber of PFC in the indirect assay. 
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FIG. 3. PFC responses of the spleens of lethally irradiated mice receiving 2 X 107 bone 
marrow cells from donors primed iv with 4 X 108 SRBC at various times before cell transfer. 
Bone marrow cells were ahvays supplemented with 5 X 107 virgin thymocytes. Each point is a 
mean value obtained from 5 mice. (0), IgM-PFC; (e), IgG-PFC; (•), IgA-PFC; addition 
of (A.) to a closed drcle or square means that the number of PP,C in the indirect assay dif-
fered not significantly from the number of PFC in the direct assay. 
Distribution of B-memory Cells in Various Lymphoid Organs 
The distribution of B-memory cells 27 \veeks after immunization was studied 
by transferring fixed numbers of nucleated cells of various lymphoid organs to-
gether with 5 X 107 virgin thymocytes and 5 X 10' SRBC into lethally irradiated 
recipients. To describe the amount of precursors of PFC (pPFC) of an organ 
quantitatively, the conception ' 1PFC capacity" was introduced and defined as 
number of cells in the organ 
number of cells transferred into the recipient 
X mean number of PFC per recipient spleen. 
To calculate the increase in the amount of pPFC caused by an iv injection of 4 X 108 
SRBC, the PFC capacity of various lymphoid organs 27 weeks after priming \Vas 
compared \vith the PFC capacity of the organs of nonimmune mice of the same 
age. Table 2 shows that cells of spleen, bone marrow, peripheral lymph nodes 
(inguinal, axillary and brachial), mesenteric lymph node, Peyer' s patches (only 
patches of the small intestine were used) and blood of the nonimmune mice were 
able to evoke a PFC response in the recipient spleen. E-xcept for bone marrow 
and Peyer's patches cells of all these organs provoked not only Ig}}{- and IgG-PFC, 
but also IgA-PFC. Transfer of thymocytes did not result in significant numbers of 
PFC in the recipient spleen. The PFC capacity of the spleen was the greatest of all 
the organs tested. In a similar experiment with lymphoid cells from mice which 
had been immunized 27 weeks previously ,,,;ith an iv injection of 4 X 108 SRB C, 
thymus, in addition to spleen, bone marrO\V, peripheral lymph nodes, mesenteric 
lymph node, Peyer' s patches and blood, was able to evoke a PFC response in the 
recipient spleen (Table 3). The cells of all these organs gave rise to IgM- and IgG-
as well as IgA-PFC in the recipient spleen. Comparison of Table 2 and Table 3 
shows that immunization of the donor mice caused an increase in PFC capacity of 
all the organs tested. Table 4 shO\VS the increase in PFC capacity of the various 
102 BENNERj MEIMA AND VAN DER J).lEULEN 
TABLE 2 
PFC CAPACITY OF VARIOus LYMPHOID ORGANS oF NoNIMMUNE MicE 
Cells transferred from: Cells/organ PFC/spleen (X103)" PFC capacity (X10')b 
(X!O") 
lgM lgG lgA lgM lgG lgA 
Spleen 11.4 441 1,464 227 2,512 8,347 1,293 
Bone marrow 33.6• 32 80 11 (n.s.)' 529 1,348 189 (n.s.) 
Peripheral lymph nodese 1.4 360 1,883 167 252 1,318 117 
Mesenteric lymph node 1.9 773 2,673 456 734 2,540 433 
Peyer's patches! 1.8 584 642 110 (n.s.) 525 578 99 (n.s.) 
Thymus 3.7 0.3 0 0 0.5 0 0 
Blood 2.5ml11 7 15 7 37 76 34 
<>Viable nucleated cells (2 X 107 ) or 0.5 ml blood were transferred 27 weeks after the beginning 
of the experiment together with 5 X 107 isologous thymocytes of nonimmune 5 week old female 
mice. Each group consisted of 5 recipient mice. PFC-assay was done on pooled spleens 7 days 
after cell transfer. 
b For definition see Results. 
c Calculation based upon data of Chervenick et al. (44). 
d There was no significant difference between the number of PFC in the direct assay and the 
number of PFC in the indirect assay. 
e Inguinal, axillary and brachial lymph nodes were used. 
I Only the patches of the small intestine were used. 
u Estimated volume per mouse. 
organs 27 weeks after an iv injection of 4 x 108 SRBC. It appears that by far the 
greatest increase in PFC capacity was found in the spleen. 
A second iv injection of 4 X 108 SRBC 5 weeks after the first one did not 
further increase the PFC capacity of spleen and bone marrow (Table 5). Addition 
TABLE 3 
PFC CAPACITY OF VARIOUS LYMPHOID ORGANS AFTER ONE iv I:"{JECTION OF 4 X 108 SRBC 
Cells transferred from: Cells/organ PFC/spleen (Xl03)a PFC capacity (Xl03)'' 
(XlO') 
lgM lgG IgA lgM lgG lgA 
Spleen 10.9 7,273 32,350 6,018 39,638 176,308 32,798 
Bone marrow 31.4" 428 1,801 413 6,720 28,276 6,484 
Peripheral lymph nodes a: 1.6 1,290 15,998 2,750 1,032 12,798 2,200 
Mesenteric lymph node 2.1 2,250 22,838 3,600 2,362 23,980 3,780 
Peyer's patches• 1.1 1,621 6,973 2,547 892 3,835 1,401 
Thymus 3.1 13 107 35 20 166 54 
Blood 2.5 mlf 4 95 8 20 475 39 
a Viable nucleated cells (2 X 107) or 0.5 ml blood were transferred 27 weeks after immunization 
of the donor mice together with 5 X 107 isologous thymocytes of nonimmune 5 week old female 
mice. Each group consisted of 5 recipient mice. PFC-assay was done on pooled spleens 7 days 
after cell transfer. 
b For definition see Results. 
c Calculation based upon data of Chervenick et al. (44). 
d Inguinal, axillary and brachial lymph nodes were used. 
c Only the patches of the small intestine were used. 
f Estimated volume per mouse. 
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TABLE 4 
INCREASE IN PFC CAPACITY AFTER ONE iv INJECTION OF 4 X 108 SRBC (X103) 
lgN!-PFC" 
Spleen 37,126 
Bone marrow 6,191 
Peripheral lymph nodes 780 
lVIesenteric lymph node 1,628 
Peyer's patches 367 
Thymus 19 
Blood -13 
JgG-PFC" 
167,961 
26,928 
11,480 
21,440 
3,257 
166 
399 
lgA-PFC" 
31,505 
6,295 
2,083 
3,347 
1,302 
54 
5 
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a. The number of PFC are obtained by subtracting the respective numbers of PFC in Table 2 
from those in Table 3. 
of 5 X 107 virgin thymocytes to spleen and bone marrmv cells did not enhance the 
PFC response of the recipient spleen markedly. Thus the number of T cells in 
these organs is not a limiting factor in this case. 
DISCUSSION 
The results presented in this paper demonstrate that after iv immunization \vith 
SRBC B- (IgM-, IgG-, IgA-) and T-memory cells appear in the bone marrow 
(Fig. 2). These B- and T -memory cells are specific for the antigen used for 
priming (Table 1). Differentiation of B-memory cells into PFC need the help of 
T cells, because prior treatment of the marrow cells v;;ith anti-theta serum and 
complement in vitro resulted in a much lower response in the spleen of the ir-
radiated recipients. It is worth noting that the inhibiting effect of the anti-theta 
treatment upon the Igl\l-, IgG- and IgA-PFC response against SRBC is about 
equal for all these categories. This is not in agreement with the literature about 
the thymic-dependence of immunoglobulin production, because Igl\1 response is 
thought to be less thymus·-dependent than IgG response (12-15). The literature 
about the thymic-dependence of IgA production is contradictory (13-15). On ac-
TABLE 5 
PFC CAPACITY OF SPLEEN AND Bmm lVIARRO\V AFTER Two iv I:«JECTIONs OF 4 X 108 SRBC 
Cells trans~ 
ferred from: 
Spleen 
Spleen 
Bone marrow 
Bone marrow 
Cells/ 
organ 
(X10') 
12.0 
12.0 
35.9" 
35.9' 
Thymus 
cells 
5 X 10i 
5 X 10' 
PFC/spleen (X103)a 
IglVI IgG IgA 
2,175 26,314 2,307 
1,944 29,860 2,911 
356 1,823 390 
391 2,403 452 
PFC capacity (X103)b 
lgM IgG IgA 
13,050 157,884 13,842 
11,664 179,160 17,466 
6,390 32,723 7,001 
7,018 43,134 8,113 
a Donor mice received the second iv injection of 4 X 108 SRBC 5 weeks after the first. Viable 
nucleated cells (2 X 107) were transferred 27 weeks after the first injection of SRBC together 
with 5 X 107 isologous thymocytes of nonimmune 5 week old female mice. Each group consisted 
of 5 recipient mice. PFC-assay was done on pooled spleens 7 days after cell transfer. 
b For definition see Results. 
"Calculation based upon data of Chervenick et al. (44). 
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count of our results we conclude that the development of IgA-PFC is thymus-
dependent to a large extent. Other cell transfer exper iments performed in this 
laboratory demonstrate that the development of IgA-PF C from B cells of non-
immune mice also requires collaboration with T cells (Van Muiswinkel and Van 
Soest, unpublished ) . T he question arises whether the PFC response of the recipient 
mice inoculated with anti-theta treated bone marrow cells is a consequence of the 
presence of a subpopulation of entirely thymus-independent B cells or is due to an 
incomplete abolishment of T cells by the anti-theta serum. Although a great excess 
of antitheta serum was used in our experiments, survival of some theta-positive 
cells can not be excluded, since T cells lose a part of their theta-antigen during 
maturation ( 16-18) . 
T he B-memory cells of the different major classes of immunoglobulins were 
demonstrated to appear in the bone marrow in the sequence IgM-IgG-IgA (F ig. 
3). The same sequence has been described with regard to phylogeny ( 19), 
ontogeny (20-23), appearance of B lymphocytes after bone marrow reconstitution 
of lethally irradiated mice (Van Muiswinkel, Van Beek and Van Soest, unpub-
lished), appearance of immunoglobulins in the serum of patients with a severe 
combined immunodeficiency after bone marrow transplantation (24, 25), and 
antibody production (1, 26, 27). 
Comparison of the results presented here with those in our previous paper ( 1) 
shows that the absence of the necessary T cells in the bone marrow coincides with 
the absence of a clear P FC response in situ after primary iv immunization with 
SRBC. The presence of IgM-, IgG-, IgA- and T-memory cells in the bone marrow 
coincides with the presence of a clear IgM-, IgG- and IgA-PFC response in situ 
after an iv boosting,.&.jnjection. Therefore we conclude that antibody formation 
against SRBC in mous~i~dent on the presence of B- and T-memory cells. 
Analysis of the P F C capacity (see Results for definition) in the different organs 
before (Table 2) and 27 weeks after (Table 3) a single iv injection of SRBC re-
veals that such an immunization results in an increased PFC capacity of spleen, 
bone marrow, peripheral lymph nodes, mesenteric lymph node, Peyer's patches, 
thymus and blood (Table 4) . It is somewhat surprising that 27 weeks after the 
beginning of the experiment the marrow of the nonimmune mice combined with 
virgin thymocytes was capable of an IgM- as well as an IgG-PFC response (Table 
2), \\·hereas at the beginning only an IgM-PFC response could be demonstrated 
(Fig. 2). Possibly a continuous stimulation by Forssmann antigens in the intestine 
(28, 29) is the underlying cause. Comparison of the PFC capacity of spleen and 
bone marrow after two iv injections of SRBC (T able 5) with the results presented 
in our p revious paper ( 1) shows a very peculiar discrepancy: late in the secondary 
response against SRBC the bone marrow contains much more PFC than the 
spleen, whereas the PFC capacity of the spleen is by far the greatest (Table 5) . 
This can not be a consequence of a lack of T -memory cells because addition of 
5 X 107 tbymocytes hardly enhanced the PFC capacity (Table 5) . Probably the 
differentiation of pPFC into PFC in the late phase of the secondary response in 
the bone marrow is greatly facilitated for some reason. 
The results presented here and in our previous paper ( 1) seem to be relevant 
with regard to the experiments of :.1cMillan et al. (30) and Hijmans et al. (31, 
32) . ::VIcMillan et al. demonstrated that human bone marrow cells cannot be stimu-
lated in vitro to antibody production against smallpox vaccine. However, in their 
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experiments human bone marrow cells appeared to be able to produce large 
amounts of IgG in vitro. Hijmans et al. presented evidence that in healthy people 
the bone marrow is a major source of immunoglobulins. VVe suggest that in these 
observations the immunoglobulins could be produced by the progeny of B-
(memory) cells against antigens continuously stimulating the lymphoid organs, 
for example intestinal bacteria. 
The appearance of B-memory cells in the thymus after iv immunization is re-
markable (Table 3). This observation is consistent 1vith the results of others using 
different experimental procedures (5, 9, 33-35). It is of interest to investigate 
whether or not these B cells behave like the other thymocytes. Experiments reveal 
that these B-memory cells are not influenced by dexamethasone-treatment in vivo 
and by anti-theta treatment in vitro (Benner, Nieima and Van der Meulen, un-
published). 
It has been reported that injection of an antigen into the thymus evokes the 
development of lymphoid follicles with germinal centers ( 36-38) and antibody 
production (36, 38, 3,9) in situ. The germinal center reactions are thought to be 
involved in the development of B-memory cells ( 40-42). In our experiments the 
appearance of B-memory cells in the thymus can be due either to the entrance of 
the antigen into the thymus or to an influx of B-memory cells. 
In conclusion it can be said that 27 weeks after an iv injection of SRBC the 
presence of B-memory cells can be demonstrated in the spleen, bone marrow, 
peripheral lymph nodes, mesenteric lymph node, Peyer's patches, thymus and the 
blood. Evidence is presented that the appearance of specific B- and T-memory cells 
in the bone marrov,· is required for the development of PFC in situ. 
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Antibody Formation m Mouse Bone Marrow 
III. EFFECTS OF ROUTE OF PRIMING AND ANTIGEN DOSE 
R. BENNER, F. MEIMA, GERDA M. VANDER MEDLEN AND w. VAN EWIJK 
Department of Cell Biology and Genetics, Erasmus University, P.O. Box !738, Rotterdam, 
The Netherlands 
(Received !st March 1974; acceptedfor publication !9th March 1974) 
Summary. The influence of the route of priming and the dose of sheep red blood 
cells (SRBC) on the IgM-, IgG- and IgA-plaque-forming cell (PFC) activity in 
mouse bone marrow during the secondary response to SRBC was studied. After 
intraperitoneal and subcutaneous priming the number of IgM-, IgG- and IgA-
PFC during the secondary response increased with the number of SRBC used for 
priming. After intravenous (i.v.) priming the priming dose-secondary response 
relationship was found to be an optimum curve for IgM-PFC as well as for IgG-
and IgA-PFC. A peak secondary response in the bone marrow was found after 
priming with I 07 and with 108 SRBC i.v. 
The appearance of IgG- and IgA-memory cells in the bone marrow after i.v. 
immunization with SRBC was shown to be dependent on the priming dose: the 
appearance oflgG-memory cells required a higher dose of SRBC than the appear-
ance oflgM-memory cells, and the appearance of IgA-memory cells required even 
more antigen. 
The effect of the booster dose upon the PFC activity was studied in mice primed 
with 107 SRBC i.v. and boosted with 104 , 106 , or 109 SRBC i.v. 2 months later. 
IgM-PFC as well as IgG- and IgA-PFC were present in spleen and bone marrow 
at each booster dose tested. In each group of mice the PFC activity in the bone 
marrow rose to a level which surpassed the level in the other lymphoid organs 
between the 7th and lOth day after the booster injection. Thus, independently ofthe 
booster dose, mouse bone marrow is the major source ofPFC during the late phase 
of the secondary response to SRBC. Mice boosted with 109 SRBC i.v. showed a 
prolonged presence oflgM-, IgG- and IgA-PFC in the thymus. Light and electron 
microscopic studies revealed the presence of plasma cells and macro phages studded 
with phagocytosed material in the thymic medulla of these mice, thus providing 
evidence for a real PFC response within the thymus. A thymic PFC response was 
absent in mice boosted with either 104 or 106 SRBC i.v. Therefore the thymic 
PFC activity during the secondary response to SRBC does depend on the booster 
dose. 
INTRODUCTION 
In previous studies it has been shown that mouse bone marrow is barely capable of 
Correspondence: Dr R. Benner, Department of Cell Biology and Genetics, Erasmus University, P .0. Box 1738, 
Rotterdam, The Netherlands. 
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producing plaque-forming cells (PFC) in the primary immune response to sheep red 
blood cells (SRBC), whereas in the secondary response to SRBC bone marrow PFC can 
be clearly demonstrated (Benner, Meima, VanderMeulen and Van Muiswinkel, 1974a). 
Evidence was presented that the PFC activity of the bone marrow in the secondary 
response is caused by the development ofPFC in situ (Benner et al., 1974a). Cell transfer 
experiments suggest that the presence of specific BandT memory cells in the bone marrow 
is required before a PFC response against SRBC can be initiated in this organ (Benner, 
Meima and VanderMeulen, !974b). The absence of appropriate memory cells is con-
sidered to be the cause of the low PFC activity in the marrow during the primary response 
to SRBC. 
From the data presented previously (Benner et al., !974a) it cannot be excluded that 
PFC activity in the bone marrow during the secondary response is a rather extraordinary 
(nonphysiological) phenomenon attributable to the high doses of SRBC used in these 
studies. In the present paper data will be presented which suggest that during the second-
ary response to SRBC (a) the presence ofPFC in the bone marrow is independent of the 
booster dose and (b) the presence of PFC in the thymus does depend on the booster dose. 
Furthermore, the effects of dose and route of priming upon the PFC activity in the bone 
marrow during the secondary response to SRBC will be discussed. 
MATERIALS AND METHODS 
Mice 
(C57Bl(Rij x CBA(Rij) F 1 female mice, 16-20 weeks old were used. They were pur-
chased from the Medical Biological Laboratory, Rijswijk, The Netherlands. 
Antigen 
SRBC were obtained from the Department of Clinical Microbiology of the Erasmus 
University, Rotterdam, The Netherlands. 
Immunization 
For primary immunization, mice received either an intravenous (i.v.), intraperitoneal 
(i.p.) or subcutaneous (s.c.) injection ofSRBC. In all experiments the second injection of 
SRBC was given i.v. The interval between first and second antigen injection was 2 or 3 
months. 
Splenectomy 
Splenectomy was performed either I day or I month before the second injection of 
SRBC. Mice were anaesthetized by an i.p. injection of 70 mglkg body weight Nembutal 
(Abbott S. A., Saint-Remy-sur-Avre, France). The incision was made in the left upper 
abdomen. The splenic vessels were tied in a single suture, then cut and the spleen removed. 
The incision was closed in two layers. There was no post-operative mortality. 
Preparation of cell suspensions 
Cell suspensions were prepared in a balanced salt solution (BSS) as described previously 
(Benner et al., 1974a). The BSS was prepared according to Mishell and Dutton (1967) 
and always supplemented with 5 per cent newborn calf serum. Thymocytes were collected 
30 minutes after an i.p. injection of the donors with 0·05 ml of a 10 per cent solution of 
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carbochrome ink (Gurr Ltd, High Wycombe, Bucks) in BSS. This facilitated differentia-
tion between thymus and adherent lymph nodes in order to avoid contamination of the 
thymocyte suspension. 
Assay for PFC 
IgM-, IgG- and IgA-PFC were determined as described previously (Benner eta!., 1974a). 
From the results of the femoral bone marrow the number ofPFC present in the marrow of 
the whole animal was estimated, using the data of Chervenick, Boggs, Marsh, Cartwright 
and Wintrobe (1968), who showed that in mice one femur contains 5·9 per cent of the 
marrow. 
Statistics 
Calculation of the 95 per cent confidence limits associated with the number of plaques 
counted, was done as described in our previous paper (Benner eta!., 1974a). The presence 
oflgG- and IgA-PFC was considered to be significant when there was no overlap between 
the upper limit in the direct assay and the lower limit in the indirect assay. 
Preparation for histological examination 
For light and electron microscopic preparation mice were fixed using a perfusion fixa-
tion device. Technical details are described in a previous paper from this laboratory (Van 
Ewijk, Verzijden, Vander Kwast and Luijcx-Meijer, 1974). 
RESULTS 
EFFECTS OF DOSE AND ROUTE OF PRIMING ON SECONDARY PFC RESPONSES IN THE BONE 
MARROW 
Mice were primed with SRBC either i.v., i.p. or s.c. The priming dose was either 105 , 
106 , 107 , 108 or 109 SRBC. Two months later all mice were splenectomized to prevent a 
regulatory effect of the spleen on the PFC activity in the bone marrow during the secondary 
response. A suppressive influence of the spleen on the PFC activity in the bone marrow 
during the secondary response has been described previously (Benner eta!., 1974a). One 
month after splenectomy all mice were boosted with 109 SRBC i.v. On the 6th day after 
boosting five animals from each group were killed and the number of IgM-, IgG- and 
IgA-PFC was determined in the femoral bone marrow. This day was chosen because the 
peak PFC activity in mouse bone marrow was previously found to occur on approximately 
the 6th day (Benner et a!., 1974a). From the results of the femoral bone marrow the 
number ofPFC present in the marrow of the whole animal was estimated, using the data of 
Chervenick et a!. ( 1968). 
Secondary IgM-, IgG- and IgA-PFC activity in bone marrow could be clearly demon-
strated after i.v. as well as after i.p. and s.c. priming at all doses tested. However, only 
after i.v. priming with 105 SRBC could no significant number of IgA-PFC be demon-
strated (Fig. I). In contrast, bone marrow of unprimed, but otherwise similarly treated 
mice contained 1240 IgM-PFC, but no significant numbers of IgG- and IgA-PFC. The 
relationship between priming dose and secondary response was different for the three 
routes of priming tested. After i.p. and s.c. priming with SRBC the numbers of PFC 
increased with the number of SRBC used for priming. Mter i.p. priming a plateau was 
reached with a dose of 107 SRBC. On the other hand after i.v. priming an optimum dose 
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of SRBC was reached. The latter curves show that this optimum dose is about 107-108 
SRBC for IgM- as well as for IgG- and IgA-PFC responses at an interval of 3 months 
between priming and boosting. 
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Fro. 1. Number of PFC in mouse bone marrow 6 days after the booster injection of SRBC. Mice were 
primed with either lOS, 106 , 107 , 108 or 109 SRBC. A second injection of 10 9 SRBC i.v. was given 3 
months later. All mice were splenectomized I month before the second injection. (e) i.v., (o) i.p. and 
(D) s.c. primed mice. Where (A) is added to an experimental point it means that the number of lgA-
PFC above the level ofigM-PFC was not significant. (a) IgM-PFC. (b) IgG-PFC. (c) IgA-PFC. 
Using the experimental approach described in the preceeding section we studied the 
appearance of the IgG- and the IgA-memory cells in the bone marrow in relation to the 
priming dose when the interval between priming and boosting was shortened from 3 to 2 
months. In this experiment mice were primed with either 105 , 3·3 x 105 , 106 or 3·3 x 106 
SRBC i.v. Two months later all mice were splenectomized and boosted within 24 hours 
with I 09 SRBC i.v. On the 6th day after boosting five mice from each group were killed 
and the number oflgM-, IgG- and IgA-PFC was determined in the femoral bone marrow. 
In mice primed with 105 SRBC only IgM-PFC were found on the 6th day after boosting 
(Fig. 2). Significant numbers of IgG- and IgA-PFC could not be demonstrated in the 
bone marrow of these mice. After priming with 3·3 x 105 SRBC IgM-PFC as well as 
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IgG-PFC were found to be present in the bone marrow. In these mice the number of 
IgM-PFC+IgA-PFC did not differ significantly from the number of IgM-PFC. Still 
higher priming doses (106 and 3·3 x 106 SRBC) resulted in the appearance of secondary 
IgA-PFC as well. Since the development of PFC in mouse bone marrow is dependent on 
the presence of specific B and T memory cells (Benner et al., 1974 b), these results indicate 
that the appearance ofigG- and IgA-memory cells specific for SRBC in mouse bone marrow 
is dose-dependent. 
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FtG. 2. Number ofPFC per mouse femur 6 days after the booster injection ofSRBC. Mice were primed 
with either 105 , 3·3x 105 , 106 or 3·3 x 106 SRBC i.v. A second i.v. injection of 109 SRBC was given 2 
months later. All mice were splenectomized 1 day before the second injection. (8) IgM-PFC, (0) 
IgG-PFC and (D) IgA-PFC. Where(.._) is added to an experimental point it means that the number of 
IgA-PFC above the level of IgM-PFC was not significant. Mter priming with 105 SRBC no significant 
numbers of IgG- and IgA-PFC were found. After priming with 3·3 x 105 no significant numbers of 
IgA-PFC could be demonstrated. In the femoral bone marrow of unprimed, but otherwise similarly 
treated mice only forty-six IgM-PFC were found. 
EFFECTS OF BOOSTER DOSE ON SECONDARY PFQ RESPONSES 
Mice were primed with 107 SRBC i.v. This dose is optimal for the appearance of 
memory cells in the bone marrow at an interval of2 months between priming and boosting 
(Benner, Meima and Van der Meulen, unpublished observations). Two months after 
priming the animals were boosted with either 104 SRBC, 106 SRBC or 109 SRBC i.v. 
Four or five mice from each group were killed at various times after boosting and the 
number of IgM-, IgG- and IgA-PFC was determined in spleen, femoral bone marrow, 
thymus, mesenteric lymph node, peripheral lymph nodes (inguinal, axillary and brachial) 
and Peyer's patches (only the patches of the small intestine were used). From the results 
obtained with the femoral bone marrow the number of PFC in the bone marrow of the 
whole animal was calculated. 
Each booster dose tested induced the appearance of IgM-, IgG- and IgA-PFC in 
spleen and bone marrow (Figs 3-5). Significant numbers of PFC in thymus, mesenteric 
lymph node, peripheral lymph nodes, and Peyer's patches were observed only after 
boosting with 109 SRBC (Fig. 6). After boosting with 104 SRBC as well as with 106 and 
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109 SRBC the numbers of PFC in the spleen rose rapidly. The peak PFC activity in the 
bone marrow was reached after the appearance of the peak numbers of PFC in the spleen 
for each booster dose. Between the 7th and lOth day after boosting the numbers of PFC 
of each antibody class in the bone marrow rose to levels which surpassed the levels in the 
spleen. After the lOth day the numbers of PFC in the bone marrow were always much 
higher than in the other lymphoid organs. 
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FIG. 3. Number of PFC in mouse spleen and bone marrow after two injections of SRBC. Mice were 
primed with 107 SRBC i.v. and boosted with 104 SRBC i.v. 2 months later. (0) Spleen and (e) bone 
marrow. Where (.A.) is added to an experimental point it means that the number oflgA-PFC above the 
level of IgM-PFC was not significant. (a) IgM-PFC. (b) IgG-PFC. (c) IgA-PFC. 
The prolonged presence ofPFC in the thymus after boosting with I 09 SRBC i.v. (Fig. 6) 
is remarkable. This thymic PFC activity was not found after boosting with 104 SRBC i.v. 
or I 06 SRBC i.v., therefore the appearance of PFC in the thymus is dependent on the 
booster dose. Histological examination of the thymus of mice primed with 107 SRBC i.v. 
and boosted with 109 SRBC i.v., showed the presence of plasma cells in the medulla. 
These plasma cells were localized predominantly around blood vessels (Figs 7-10). Close 
investigation of the thymus of normal mice did not reveal the presence of plasma cells. 
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In the thymic medulla of the immune mice cells were less densely packed compared with 
control thymus. In addition many macrophages and granulocytes were observed in the 
thymic medulla of these mice. Unlike granulocytes, macrophages were found to be closely 
associated with blood vessels (Fig. 9). 
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Fw. 4. Number of PFC in mouse spleen and bone marrow after two injections of SRBC. Mice were 
primed with 107 SRBC i.v. and boosted with 106 SRBC i.v. 2 months later. (o) Spleen and (e) bone 
marrow. \Vhere (.a.) is added to an experimental point it means that the number of lgG. or IgA.PFC 
above the level of IgM-PFC was not significant. (a) IgM-PFC. (b) IgG-PFC. (c) IgA-PFC. 
Analysis of the ratio of IgA-PFC: IgM-PFC in spleen, bone marrow and thymus during 
the secondary response reveals that this ratio is different in these three organs. From Figs 
3-6 it can be calculated that in general this ratio is about I or less in spleen, about 1·5 in 
bone marrow and about 2 in thymus. 
DISCUSSION 
The presence of specific B and T memory cells in mouse bone marrow is required before 
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In the thymic medulla of the immune mice cells were less densely packed compared with 
control thymus. In addition many macrophages and granulocytes were observed in the 
thymic medulla of these mice. Unlike granulocytes, macrophages were found to be closely 
associated with blood vessels (Fig. 9). 
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Fw. 4. Number of PFC in mouse spleen and bone marrow after two injections of SRBC. I\1ice were 
primed with 107 SRBC i.v. and boosted with 106 SRBC i.v. 2 months later. (0) Spleen and (e) bone 
marrow. Where (.A.) is added to an experimental point it means that the number of IgG- or IgA-PFC 
above the level of IgM-PFC was not significant. (a) IgM-PFC. (b) IgG-PFC. (c) IgA-PFC. 
Analysis ofthe ratio oflgA-PFC:IgM-PFC in spleen, bone marrow and thymus during 
the secondary response reveals that this ratio is different in these three organs. From Figs 
3-6 it can be calculated that in general this ratio is about I or less in spleen, about 1·5 in 
bone marrow and about 2 in thymus. 
DISCUSSION 
The presence of specific B and T memory cells in mouse bone marrow is required before 
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The question arises whether the B memory cells in the bone marrow, which are stimu-
lated in situ to antibody synthesis (Benner eta/., 1974a), also originate in situ in this organ 
or derive from other lymphoid organs. The generation of B memory cells is thought to 
take place in germinal centre reactions (Thorbecke, 1969; Durkin and Thorbecke, 1971; 
Nieuwenhuis, 1971). Although germinal centres are reported to be occasionally present 
in bone marrow (Duhamel, 1968), we could not find these reaction centres after primary 
immunization with SRBC (Van Ewijk and Benner, unpublished observations). Since B 
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FIG. 6. Number ofPFC in mouse mesenteric lymph node, peripheral lymph nodes, thymus and Peyer's 
patches. Mice were primed with 107 SRBC i.v. and boosted with 109 SRBC i.v. 2 months later. The 
organs were obtained from the very same mice used to determine the numbers of PFC in spleen and 
bone marrow (Fig. 5). C•) Mesenteric lymph node, (0) peripheral lymph nodes, (e) thymus and (D) 
Peyer's patches. Where (.A.) is added to an experimental point it means that the number of IgG- or 
IgA-PFC above the level of IgM-PFC was not significant. (a) IgM-PFC. (b) IgG-PFC. (c) IgA-PFC. 
memory cells recirculate (Miller and Sprent, 1971) it is quite possible that B memory cells 
which are generated in spleen and lymph nodes circulate through and home in bone 
marrow. The different effects of the priming dose after either i.v., i.p. or s.c. priming (Fig. 
I) might then be due to a difference between spleen and lymph nodes in dose-dependence 
of the development of B memory cells. However, it is also possible that only spleen-
derived B memory cells are able to home in bone marrow. In that case the s.c. priming 
effect in terms of secondary PFC responses in bone marrow is due to s.c. antigens entering 
the circulation and stimulating the spleen. Then the priming dose-secondary response 
curves after s.c. priming represent the left part of the curves after i.v. and i.p. priming. 
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FIG. 7. Low magnification of mouse thymus 6 days after the second injection of SRBC. Mice were 
primed with 107 SRBC i.v. and boosted with 109 SRBC i.v. 2 months later. A 1-,um Epon section, 
stained with I per cent Toluidine Blue in 0·1 M borax buffer. Blood vessels (V) are cleared from blood, 
due to the perfusion fixation. C = cortex. M = medulla. 
FIG. 8. Thymic medulla. Higher magnification of selected area of Fig. 7· Plasma cells (arrows) are 
localized around blood vessels. 
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20 f.Lm 
FIG. 9. Thymic medulla of an immune mouse. Plasma cells and macrophages are closely associated 
with blood vessels. 
FIG. 10. Electron micrograph of a plasma cell with dilated rough endoplasmic reticulum {RER) 
observed in the thymic medulla of an immune mouse. G = Golgi region. 
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The sequence of appearance of B memory cells of different antibody classes in the bone 
marrow after increasing doses ofSRBC was found to be IgM, IgG, IgA (Fig. 2). The same 
sequence has been described with regard to the dose-dependence of splenic PFC in the 
primary response (Wortis, Dresser and Anderson, 1969) and the appearance in time of 
splenic PFC during the primary response (Wortis et al., 1969; Benner et al., 1974a). The 
preferential IgM-PFC response during the first days of a primary response may be due to a 
preponderance of IgM-B cells at the sites of first encounter between antigen, B cells and 
T cells. In the secondary response to SRBC IgM-, IgG- and IgA-PFC appeared nearly 
simultaneously and independently of the booster dose (Figs 3-5), probably due to the high 
numbers of specific BandT cells in spleen and bone marrow of immune mice (Cunning-
ham and Sercarz, 1971; Niederhuber and Moller, 1973; Benner eta/., 1974b). 
Another difference between primary and secondary PFC response is the interval between 
immunization and time of peak PFC activity. In the primary response to SRBC the peak 
PFC activity in the spleen is delayed with suboptimal doses of antigen (Sercarz and Byers, 
1967). This phenomenon was less prominent in spleen and bone marrow during the 
secondary response to SRBC (Figs 3-5). The amount of specific T cells in the spleen of 
non-immune mice is probably limiting for a maximal PFC response to SRBC (Campbell, 
1972; Zaalberg, Vander Meul and Rossi, 1973). At higher doses ofSRBC the number of 
specifically stimulated B and T cells will increase. Thus the chance of interaction between 
antigen, B cells and T cells will be enhanced. Consequently the peak PFC activity in the 
primary response to SRBC is reached earlier with high antigen doses. After antigenic 
stimulation the number of specific B and T cells in spleen and bone marrow also increase. 
The abundance of specific B and T cells in spleen and bone marrow of immune mice 
(Benner et al., 1974b) is the probable cause of the weaker antigen dose-dependence of the 
time interval between secondary immunization and peak PFC activity in the secondary 
response. 
The thymus is generally considered to be a primary lymphoid organ, since it produces 
lymphocytes which are of major importance for the immunological capacity of other 
lymphoid organs (Miller and Davies, 1964). Small numbers of PFC were reported to be 
present in the thymus during the late phase of the primary response after i.p. immuniza-
tion with SRBC (Chaperon, Selner and Claman, 1968; Anderson and Dresser, 1972). It 
is difficult to prove that PFC activity in a thymus cell suspension is due to the presence of 
PFC in the thymus itself, since this organ is closely associated with the adherent lymph 
nodes. We tried to avoid contamination of the thymocyte suspension with lymph node cells 
by using the carbon-injection technique ofLeckband and Boyse (1971). After priming with 
107 SRBC i.v. and boosting with 109 SRBC i.v., but not with the lower doses, a clear PFC 
activity in the thymus resulted (Fig. 6). Thymic PFC activity could be due to migration of 
PFC from the spleen into the thymus (Chaperon et al., 1968). However, the possibility of 
differentiation of B cells into PFC within the thymus has to be considered. The develop-
ment of anti-SRBC PFC within the thymus requires the presence of appropriate B cells 
in situ and entrance of antigen into the thymus. In a previous paper it was reported that 
after i.v. priming with SRBC B memory cells appear in the thymus (Benner eta/., 1974b). 
Okumura and Tada (1973) showed that thymocytes can be primed in situ by i.p. injected 
heterologous red blood cells. We suggest that in the late phase of the primary response and 
after boosting with the same antigen B memory cells can differentiate with the help of 
specific T cells into PFC within the thymus. Histological examination of the thymus of 
mice primed with 107 SRBC i.v. and boosted with 109 SRBC i.v. provides evidence for 
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such a differentiation in situ. The presence of macrophages studded with phagocytosed 
material and the presence of relatively large numbers of plasma cells in the neighbourhood 
of these macrophages (Fig. 9) suggest that the thymus can act as a secondary lymphoid 
organ. 
The large proportion of IgA-PFC in the thymus (Fig. 6) is remarkable. By immuno-
fluorescent analysis Allen and Porter (1973) showed a high percentage of the few plasma 
cells present in piglet thymus to contain IgA. Possibly the endodermal origin of the thymus 
is the underlying cause. 
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Antibody Formation in Mouse Bone Marrow 
IV. The Influence of Splenectomy on the Bone Marrow Plaque-Forming 
Cell Response to Sheep Red Blood Cells 
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Mouse bone marrow is barely capable of plaque-forming cell (PFC) activity dur~ 
ing the primary response to sheep red blood cells ( SRBC). However, during the 
secondary response, it becomes the major center of activity containing IgM-, IgG-, 
and IgA-PFC. In the present paper· the influence of splenectomy was studied on 
primary and secondary PFC activity in the.bone marrow. Differences in primary and 
secondary bone marrow PFC responses are probably related to the presence of B and 
T memory cells in situ. Therefore the effect of splenectomy on the appearance of 
B and T memory cells in the bone marrow was also investigated . .Splenectomy before 
intravenous (iv) immunization with 4 X 108 SRBC prevented any primary PFC activ;-
ity in the bone marrow. The influence of splenectomy before priming on secondary 
PFC activity in the bone marrow depended on the priming dose of SRBC. Splenec-
tomy before priming with 107 SRBC iv completely prevented lgM-, IgG-, and IgA-
PFC activity in the bone marrow upon subsequent boosting with 4 X 108 SRBC iv. 
By means of cell transfer experiments it was shown that after splenectomy no B or 
T memory cells appeared in the bone marrow after priming with 107 SRBC iv. The 
effect of splenectomy on both secondary PFC activity and appearance of B and T 
memory cells in the bone marrow could be partly overcome by iv priming with a 
higher antigen dose of 4 X 108 SRBC. Cell transfer experiments showed that splenec-
tomy before priming with 107 SRBC iv not only interfered with the appearance of B 
and T memory cells in the bone marrow, but also with the appearance of B·.fuemory 
cells in peripheral lymph nodes, mesenteric lymph node, Peyer's patches, thymus, and 
blood. This indicates that after immunization with 107 SRBC iv all B and T memory 
cells which appear at extra splenic sites, are generated in the spleen. Immunization 
of Splenectomized mice with 4 X lOS SRBC iv did induce the appearance of B memory 
cells in peripheral lymph nodes, mesenteric lymph node, Peyer's patches, thymus, and 
blood. We suggest that small amounts of a high dose of iv inoculated SRBC can 
induce the generation of B memory cells in lymph nodes and Peyer's patches. 
INTRODUCTION 
During the primary response to sheep red blood cells (SRBC), plaque-forming 
cells (PFC) can be barely demonstrated in mouse bone marrow. However, a very 
distinct IgM-, IgG-, and IgA-PFC activity is present in this organ during the 
secondary response (I. 2). Independent of the booster dose this activity in the 
bone marrow rises to a level which surpasses the total level in all the other 
lymphoid organs (2). Evidence was presented that the antibody-forming cells 
which· appear in the bone marrow can be generated in situ. To initiate such a bone 
Copyright© 1975 by Aeademic Preao;, Inc. 
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marrow PFC response to SRBC, the presence of specific B and T memory cells 
seems to be required ( 3) . 
The site of origin of the B and T memory cells which appear in the bone mar-
row after intravenous (iv) priming with SRBC (3) is not clear. B memory cells 
are thought to be generated in germinal centre reactions ( 4-6). These germinal 
centre reactions are only incidentally found in bone marrow (7, 8), but abun-
dantly present in spleen and lymph nodes ( 6). 
About the origin of T memory cells Miller and Mitchell (9) hypothesized in 
1969 that "lymphocytes which emigrate from the thymus are short-lived cells and 
can establish a progeny of long-lived recirculating cells only if they interact with 
antigens in the appropriate environment of the secondary lymphoid tissues". 
In the present paper data will be presented about the influence of ·splenectomy 
on the bone marww PFC response to SRBC. In addition cell transfer experi-
ments are described which deal with the origin of the B and T memory cells 
which appear in the bone marrow after iv priming with SRBC. The results sug-
gest that the spleen is the most important breeding site of these memory cells after 
iv antigen administration. 
MATERIALS AND METHODS 
Mice. (C57BL/Rij X CBAjRij)F1 female mice, 16-20 wk old were used. 
They were purchased from the Medical Biological Laboratory, Rijswijk, The 
Netherlands, and the Laboratory Animals Centre of the Erasmus University, 
Rotterdam, The Nether lands. 
Antigen. Sheep red blood cells were obtained from the Department of Clinical 
Microbiology of the Erasmus University, Rotterdam, The Netherlands. Before 
use the cells were washed three times in phosphate buffered saline (pH 7.2). 
Immunization. Mice were primed with an iv injection of either 107 or 4 X 108 
SRBC in a volume of 0.5 ml. For secondary immunization mice received an iv 
injection -of 4 X 108 SRBC. The interval between first and second antigen injec-
tion was 4 mo. 
Splenectomy. Splenectomy and sham-splenectomy were performed at least 1 mo. 
before injection of SRBC. Mice were anaesthetized by an intraperitoneal (ip) 
injection of 70 mg/kg body wt Nembutal (Abbott S.A., Saint-Remy-sur-Avre, 
France). The incision was made in the left upper abdomen. For splenectomy the 
splenic blood vessels were; tied in a single suture, then cut and the spleen removed. 
The incision was closed in two layers. There 'Yas no postoperative mortality. 
Preparation of cell suspensions. Cell suspensions were prepared in a balanced 
salt solution (BSS) (10) as described previously (1). Biood was obtained by 
cardiac puncture and immediately heparinized ( 5 U /ml). Thymocytes were col-
lected 30 min after an ip injection of the donors with 0.1 ml of a 1 o/a solution of 
carbochrome ink (Gui-r Ltd., High Wycombe, Buckinghamshire, England) in 
BSS. This facilitated differentiation between thymus and adherent lymph nodes 
in order to avoid contamination of the thymocyte suspension. CorticoSteroid re-
sistant thymocytes (CRT) were obtained from 6-wk-old mice injected ip with 
30 mg of the synthetic corticosteroid Dexamethasone sodium phosphate (Merck & 
Co., Rahway, New Jersey) per kilogram body weight 2 days previously. 
Isolation of nucleated cells from peripheral blood. Nucleated cells were .isolated 
from mouse blood using a modification of the Ficoll-Isopaque· system described by 
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Boyum (11). The Ficoll-Isopaque mixture was obtained by mixing 2 parts I;o-
paque (Nyegaard & Co., Oslo, Norway), 3 parts Ficoll (Pharmacia, Uppsala, 
Sweden) 9% and 2 parts of a 3.5% solution of bovine serum albumin in distilled 
water. Final density was 1.115 gjml. Using this method a minimum of 70;Yo of 
the nucleated cells were recover-ed. 
Cell counts. Viable cells were counted in a haernocytometer using 0.2% trypan, 
blue in BSS as a diluent. 
Irradiation. The recipient mice received 850 rad whole body irradiation gen-
erated in a Philips MUller MG 300 X-ray machine. Animals were irradiated in 
well-aerated circular Perspex cages. Physical constants of the irradiation were 
described previously ( 3). Radiation control mice died in 9-16 days. 
Cell transfer. Recipients were injected iv with the appropriate cell suspension 
and 5 X 108 SRBC within 4 hr after irradiation. On the fourth day all mice were 
boosted with 5 X )0' SRBC ip. PFC in the spleen of recipient mice were deter-
mined 7 days after cell transfer. Seven days after cell transfer PFC activity in 
the recipient spleen is maximal. Each group consisted of five mice. 
Assay for PFC. IgM-, IgG-, and IgA-PFC were determined as described pre-
viously ( 1). The monolayer plaque assay sides were made using a double-sided 
adhesive plastic film ( N eschen International, Bllckeburg, Western Germany) as 
described by Majoor, Van'! Veer, and Zaalberg (12). Calculation of the 95;Yo 
confidence limits associated with the number of plaques counted was done as de-
scribed previously (I). The presence of IgG- and IgA-PFC was accepted as sig-
nificant when there was no overlap between the upper limit in the direct assay 
and the lower limit in the indirect assay. 
Cakulation of total bone marrow PFC activity. Bone marrow PFC activity was 
determined in the femoral marrow. From the results of the femoral bone marrow 
the number of PFC present in the marrow of the whole animal was estimated 
using the data of Chervenick and co-workers (13), who showed that in mice one 
femur contains 5.91o of the total marrow. Comparison of the PFC responses 
evoked by fixed numbers of nucleated bone marrow cells from femur, tibia, hu-
merus, and rib (Table 1) indicated that IgM-, IgG-, and IgA-PFC activity in 
various compartments of mouse bone marrow is about the same. 
Serum titration. Agglutinating antibody titres were assayed in duplicate with 
the standard twofold dilution method using a I ;Yo solution of SRBC. The samples 
were tested for the presence of 2-mercaptoethanol (2-ME) sensitive and 2-ME 
·resistant antibodies. For determination of 2-ME resistant antibody titres, the sera 
were diluted 1:4 with BSS before dilution v/v with 0.2 mol 2-ME. After incuba-
tion for 2 hr at room temperature, the sera were titrated according to the standard 
method. 
RESULTS 
Effects of Splenectomy on Primary and Secondary PFC Activity in the Bone 
IIi arrow 
Since the spleen is the major organ producing PFC during the primary response 
to iv inoculated SRBC, it was of interest to investigate whether the bone marrow 
can take over this function of the spleen some time after splenectomy. To study 
this, mice were splenectomized 7 rna before first immunization with SRBC. Al-
though 7 rna is about a quarter of their lifetime, the bone marrow of these mice 
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TABLE 1 
COMPARISON OF PFC AcTIVITY IN VARIOUS COMPARTMENTS OF MoUSE BONE MARROW 
DURING THE SECONDARY RESPONSE TO SRBC 
Source of PFC/107 viable nucleated cells" 
bone marrow 
cells lgM lgG lgA 
Femur 820~ 4914' 1568 
(521-1291) (3294-7329) (1004-2449) 
Tibia 1037 4648 1935 
(520-2068) (2049-10,541) (1251-2991) 
Humerus 1640 4971 1882 
(695-3868) (2618-9439) (87Q--4070) 
Rib~ 1667 5795 2137 
(793~3505) (2772-12,118) (1040-4389) 
"Mice were primed with 107 SRBC iv and boosted with 4 X 108 SRBC iv 4 mo later. PFC~ 
assay was done 7 days after the booster injection. 
~Geometric mean and 95% confidence limits. 
c Marrow cells from ribs were obtained by gently breaking the ribs with mortar and pestle. 
Cells were separated from bone fragments by squeezing the suspension through a nylon~gauze 
filter with 30 ,urn openings. 
was still unable to compensate for the absence of the spleen by an increased PFC 
activity. It was even found that PFC activity in the bone marrow of these splenec-
tomized mice was completely absent, whereas in the bone marrow of sham-splenec-
tomized mice PFC were found of all three antibody classes (Fig. 1). The 2-ME 
sensitive and 2-ME resistant antibody titres in the splenectomized mice were also 
very deficient (Fig. 2), demonstrating that other lymphoid organs did not com-
pensate for the absence of spleen-derived antibodies. 
The influ~nce of splenectomy upon secondary PFC activity in the bone marrow 
was studied in three groups of mice primed with 107 SRBC iv. One group was 
sham-splenectomized 2 mo before priming, and again 3 mo thereafter. The second 
group was splenectomized 2 mo before, and sham-splenectomized 3 mo after prim-
ing, and in the third group these operations were reversed. Four months after 
priming all mice were boosted with 4 X 10' SRBC iv and the development of the 
secondary response was followed in spleen, bone marrow, peripheral lymph nodes 
(inguinal, axillary, and brachial), mesenteric lymph node, Peyer's patches (only 
the patches of the small intestine were used), thymus, and blood. Of all these 
organs tested a significant PFC activity was found only in spleen and bone mar-
row. Bone marrow PFC occurred only in mice which were two times sham-splenec-
tomized or splenectomized 1 mo before the booster injection (Fig. 3). During this 
secondary response the PFC activity in the bone marrow of mice two times sham-
splenectomized rose to a level which surpassed the level in the spleen at about 
the seventh day for IgM-PFC as well as for IgG- and IgA-PFC. The bone mar-
row PFC activity of mice splenectomized 1 mo before the booster injection rose 
to a higher level than in the former group of mice (Fig. 3). In a previous paper 
evidence was presented that this higher PFC activity is probably due to the absence 
of spleen-derived antibodies ( 1). In the bone marrow of mice splenectomized 
before priming with 10' SRBC iv no significant IgM-, IgG, and IgA-PFC activity 
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FIG. 1. Number of PFC in spleen (0) and b~ne marrow (e) of mice sham-splenectomized 
7 mo be~ore immunization with 4 X l(f SRBC iv. In the bone marrow (X) of mice splenecto-
mized 7 mo before injection of 4 X 108 SRBC iv no significant PFC activity was found at 
any time after immunization. Where (..t..) is added to an experimental point, the number of 
lgG-PFC or IgA-PFC above the number of IgM-PFC was not significant. 
could be demonstrated during the secondary response (Fig. 3). In these mice 
2-ME sensitive and 2-ME resistant antibody titeres during rthe secondary re-
sponse were greatly impaired as compared with the serum antibody titres of the 
other two groups of mice (Fig. 4) . Since these secondary response titres were as 
low as primary response titres of splenectomized mice (Fig. 2) it can be concluded 
that splenectomy before priming with 10' SRBC iv completely prevented the 
develoment of a secondary type antibody response after boosting. 
In another experiment it was investigated whether this influence of splenec-
tomy before priming on the secondary response can be overcome by using a higher 
antigen dose for primary immunization. In this experiment splenectomized and 
sham-splenectomized mice were immunized with 4 X 108 SRBC iv 2 mo after 
surgery. Four months later both groups of mice were boosted with a second injec-
tion of 4 X 108 SRBC iv and the development of the secondary PFC response of 
the bone marrow was followed. In contrast to the experiment in which the. miee 
were primed with 107 SRBC, splenectomized mice now showed a clear IgM-, 
IgG-, and IgA-PFC activity in the bone marrow (Fig. 5). However, the PFC 
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FIG. 2. 2-ME-sensitive and 2-ME-resistant antibody titres in the sera of· mice sham-splenec-
tomized ( 8) or splenectomized ( •) 7 mo before immunization with 4 X 108 SRBC iv. The 
sera were obtained from the same mice used to determine PFC activity 'in spleen and bone 
marrow (Fig. 1). For comparison, the secondary response of mice splenectomized before prim-
ing with 107 SRBC iv ( 0) is given. 
activity in the bone marrow of sham-splenectomized mice, which was shown to 
be impaired by the presence of the spleen (Fig. 3) was higher throughout the 
experiment. Therefore priming with 4 X 108 SRBC cannot completely overcome 
the influence of splenectomy before priming upon secondary PFC activity in the 
bone marrow. 
Effects of Splenectomy on the Appearance of B and T Memory Cells in the Bone 
Marrow 
The development of PFC in mouse bone marrow during the secondary re-
Bponse to SRBC was previously concluded to be dependent on the presence of 
specific B and T memory cells in the bone marrow ( 3). Therefore we also 
studied the effects of splenectomy before the priming antigen injection upon 
the appearance of B and T memory cells in the bone marrow. Since it was 
previously demonstrated that after immunization with 4 X 108 SRBC iv, B 
memory cells do not only appear in spleen and bone marrow, but also in peri-
pheral lymph nodes, mesenteric lymph node, Peyer' s patches, thymus, and blood 
( 3), the influence of splenectomy upon the appearance of B memory cells was 
also studied in these organs. The appearance of B and T memory cells was 
studied by means of cell transfer experiments performed 4 mo after primary 
immunization of five groups of mice. One group was sham-splenectomized and 
not immunized. Another group was splenectomized and primed with 107 SRBC 
iv. The third group was sham-splenectomized and immunized with 107 SRBC 
iv. The fourth group of mice was splenectomized before immunization with 
4 X 108 SRBC iv. The last group was sham-splenectomized and primed with 
4 X 10' SRBC iv. 
Transfer of 2 X 107 viable bone marrow cells from nonimmunized sham-
splenectomized mice into lethally irradiated mice challenged with 5 X 10' SRBC 
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FIG. 3. Number of PFC in mouse spleen and bone marrow after two injections of SRBC iv. 
Spleen ( 0) and bone marrow (e) of mice sham-splenectomized before priming and before 
boosting. Bone marrow ( •) of mice sham-splenectomized before priming and splenectomized 
before the booster injection. In the bone marrow (X) of mice splenectomized before first and 
sham-splenectomized before second immunization no significant PFC activity was found at any 
time after second antigen injection. In all groups -of mice, no significant PFC activity was found 
in peripheral lymph nodes, mesenteric lymph node, Peyer's patches, thymus, and blood. All 
mice were primed with 107 SRBC iv and boosted with 4 X 108 SRBC iv 4 mo later. Where 
(A) is added to an experimental point, the number of IgA-PFC above the number -of lgM-
PFC was not significant. 
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FIG. 4. 2-ME-sensitive and 2-ME-resistant serum antibody titres after two m]ections of 
SRBC iv. The sera were obtained from the same mice used to determine PFC activity during 
secondary response (Fig. 3). Mice splenectomized before priming (0), mice splenectomized 
before the booster injection ( •) and mice which were not splenectomized (e). 
evoked very small numbers of PFC in the spleen of the recipient mice (Table 
2). The same result was obtained with bone marrow cells from mice splenec~ 
tomized before priming with 10' SRBC (Table 3. In contrast, transfer of bone 
marrow cells from sham-splenectomized primed animals evoked increased num-
bers of PFC of all antibody classes in the recipient spleen (Table 4). Part of 
the deficit in bone marrow of the splenectomized and the nonimmunized mice 
could be corrected by adding I 0' CRT at the moment of cell transfer. This in-
dicates that splenectomy interferes with the appearance of T memory cells in 
the b~ne marrow. As shown in Table 4, transfer of bone marrow cells from mice 
sham-splenectomized before priming with 10' SRBC iv together with 10' CRT 
gave an increased IgM-, IgG-, and IgA-PFC response in the recipient spleen as 
compared with transfer of bone marrow cells from nonimmune mice and CRT 
(Table 2). The response evoked by bone marrow cells from the splenectomized 
primed mice together with CRT (Table 3) was as low as the response evoked by 
bone marrow cells from nonimmunized mice and CRT (Table 2). Thus splenec-
tomy before priming with 10' SRBC iv not only interfered with the appearance 
of T memory cells, but also with the appearance of B- memory cells in the bone 
marrow. Although both B and T memory cells appeared in the bone marrow of 
mice sham-splenectomized before priming with 107 SRBC the number of T mem-
ory cells was not optimal for a maximal PFC response since addition of 107 
CRT to these bone marrow cells improved the PFC response in the recipient 
spleen (Table 4). Four months after immunization of splenectomized mice with 
4 X 108 SRBC iv the bone marrow of these mice contained both B and T mem-
ory cells as shown by comparing Tables 2 and 5. Bone marrow cells from 
·sham-splenectomized mice immunized with 4 X 108 SRBC iv evoked a some-
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FIG. 5. Number of PFC in mouse bone marrow after two injections of 4 X 108 SRBC iv. 
,The second injection was given 4 mo after the first. Mice were sham-splenectomized (e) or 
splenectomized (0) before the firs-t antigen-injection. Where (A) is added to an experimental 
point, the number of IgA-PFC above the number of lgM-PFC was not significant. 
what higher PFC response in the recipient spleen (Table 6) than did bone 
marrow cells from splenectomized mice immunized with that antigen dose (Ta-
ble 5). This was found after transfer of bone marrow cells alone .as well as 
after transfer of bone marrow cells together with CRT. 
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TABLE 2 
ADOPTIVE PFC RESPONSE BY CELLS FROM VARIOUS LYMPHOID ORGANS OF 
NONPRIMED SHAM-SPLENECTOMIZED MICE 
Cells transferred froma CRT PFC/recipient spleen (X 103)c 
addedb 
lgM IgG !gA 
Spleen 209 901 190 
Spleen 107 262 1406 301 
Bo'ne marrow 0.7 0.4 0.0 
Bone marrow 107 26 71 2 (ns)' 
Peripheral lymph nodes 107 455 1796 278 
Mesenteric lymph node 107 490 2300 321 
Peyer's pat~es 107 162 381 12 (ns) 
Thymus 107 0.2 0.0 0.0 
Blood 107 3 25 2 
107 <0.2 <0.2 <0.2 
"Viable nucleated cells (2 X 107) or 0.25 ml blood were transferred 6 mo after sham-splenectomy. 
b rorticosteroid resistant thymocytes (CRT) were obtained from 6-wk-old mice ip injected with 
Dexamethasone-sodium-phosphate 2 days previously. 
~ Arithmatic mean of the values obtained from five recipient mice. PFC-assay was done 7 days 
after cell transfer. 
a There was no significant difference between the number of PFC in the direct assay and the 
number of PFC in the indirect assay. 
The appearance of B memory cells in the other lymphoid organs was studied 
by transfer of a fixed number of viable nucleated cells together with 5 X 10' 
SRBC and 107 CRT into lethally irradiated recipients. By comparison of Tables 
2, 3, and 4 it can be seen that splenectomy before immunization with 10' SRBC 
TABLE 3 
ADOPTIVE PFC REsPONSE BY CELLS FROM VARIOUS LYMPHOID ORGANS OF 
MICE SPLENECTOMIZED BEFORE PRIMING WITH 107 SRBC iv 
Cells transferred from" CRT PFC(recipient spleen (X 103)c 
added" 
IgM IgG lgA 
Bone marrow 0.6 0.6 0.2 (ns)' 
Bone marrow 107 33 87 6 (ns) 
Peripheral lymph nodes 107 261 2240 170 
Mesenteric lymph node 107 519 1887 401 
Peyer's patches 107 246 644 35 (ns) 
Thymus 107 0.3 0 0 
Blood 107 6 21 4 
107 <0.2 <0.2 <0.2 
"Viable nucleated cells (2 X 107) or 0.25 ml blood were transferred 4 mo after iv priming of 
splenectomized mice with 107 SRBC. 
l> Corticoste~oid resistant thymocytes (CRT) were obtained from 6-wk-old mice ip injected with 
Dexainethasone-sodium-phosphate 2 days previously. 
e Arithmatic mean of the values obtained from five recipient mice. PFC-assay was done 7 days 
after cell transfer. 
a There was no significant difference between the number of PFC in the direct assay and the 
number of PFC in the indirect assay. 
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TABLE 4 
ADOPTIVE PFC RESPONSE BY CELLS FROM VARIOUS LYMPHOID ORGANS OF 
MICE SHAM-SPLENECTOMIZED BEFORE PRIMING WITH 107 SRBC iv 
Cells transferred froma CRT PFC/recipient spleen (X 103)c 
added" 
lgM lgG lgA 
Spleen 1823 14,468 1992 
Spleen 10' 2222 17,189 1574 
Bone marrow 178 396 104 
Bone marrow 10' 290 1498 248 
Peripheral lymph nodes 10' 533 9218 463 
Mesenteric lymph node 10' 1540 16,585 1315 
Peyer's patches 10' 418 1649 537 
Thymus 10' 16 142 25 
Blood 10' 37 144 21 
10' <0.2 <0.2 <0.2 
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"Viable nucleated cells (2 X 107) or 0.25 ml blood were transferred.4 mo after iv priming of 
sham-splenectomized mice with 107 SRBC. 
~Corticosteroid resistant thymocytes (CRT) were obtained from 6-wk-old mice ip injected with 
Dexamethasone-sodium~phosphate 2 days previously. 
c Arithmatic mean of the ~lues obtained from five recipient mice. PFC-assay was done 7 days 
after cell transfer. 
iv prevents the appeara.Ltce of B memory cells not only in the bone marrow, but 
also in peripheral lymph nodes, mesenteric lymph node, Peyer's -patches, thymus, 
and blood. Immunization of splenectomized mice with a dose of antigen as high 
as 4 X 10' SRBC induced the appearance of IgM-, IgG-, and IgA-B memory 
cells in the various lymphoid organs. The cells of these organs toge~her with 
CRT evoked enhanced numbers of IgM-, IgG, and IgA-PFC in the recipient 
TABLE 5 
ADoPTIVE PFC REsPONSE BY CELLS FROM VARIOus LYMPHOID ORGANS oF 
MICE SPLENECTOMIZED BEFORE PRIMING WITH 4 X 108 SRBC iv 
Cells transferred from" CRT PFC/recipient spleen (X 103)a 
added" 
IgM lgG lgA 
Bone marrow 64 210 46 
Bone marrow 10' 194 816 191 
Peripheral lyrriph nodes 10' 1175 6488 1055 
Mesenteric lymph node 10' 1133 10,055 1253 
Peyer's patches 10' 364 2040 441 
Thymus 10' 17 102 36 
Blood 10' 26 78 20 
10' <0.2 <0.2 <0.2 
"Viable nucleated cells (2 X 107) or 0.25 ml.blood -were transferred 4 mo after iv prim~ng of 
Splenectomized mice with 4 X 108 SRBC. 
& Corticosteroid resistant thymocyt~s (CRT) were -obtained from 6~wk-Old mice ip injected 
with Dexamethasone-sodium-phosphate 2 days previously. 
c Arithmatic mean of the vaJues obtained from five recipient mice. PFC-assay was done '1 days 
·after cell trans£ er. 
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spleen (Tables 2 and 5). These PFC responses were somewhat lower than after 
transfer of lymphoid cells from sham-splenectomized mice iv immunized with 
4 x 10' SRBC (Table 6). 
DISCUSSION 
Immunization of mice with SRBC induces the appearance of B and T memory 
cells in the bone marrow (this paper and Ref. 3). B memory cells were found 
for IgM as well as for IgG- and IgA-PFC responses. Immunocompetent 
B cells ( 3) and T cells ( 14, 15) were also reported to appear "spontaneously" 
in the bone marrow during adult life. Possibly these B and T cells are long-
lived memory cells for environmental antigens stimulating the lymphoid system. 
Autoradiographic studies are consistent with this supposition, since very recently 
it was shown that in mice essentially no short-lived lymphocytes migrate to the 
bone marrow (16, 17) while both long-lived B and T lymphocytes are normal 
residents in the marrow (18). 
The capacity of mouse bone marrow to show PFC activity during the sec-
ondary response to SRBC was previously shown to coincide with the presence 
of both B and T memory cells in situ ( 3.) Therefore we suggested antibody 
fOrmation in mouse bone marrow to be a memory-dependent phenOmenon ( 3). 
The splenectomy experiments reported in this paper favour this idea. Sple-
nectomy before priming with 107 SRBC iv not only interferes with the appearance 
of B and T memory cells (Table 7) but also prevents PFC activity in the bone 
marrow of these mice after the booster injection (Fig. 3). Priming of sple-
nectomized mice with 4 X 108 SRBC did induce the appearance of B and T 
memory cells in the bone marrow (Table 7). This again coincides with the 
TABLE 6 
ADOPTIVE PFC RESPONSE BY CELLS FROM VARIOUS LYMPHOID ORGANS OF 
MICE SHAM-SPLENECTOMIZED BEFORE PRIMING WITH 4 X 108 SRBC iv 
Cells transferred from" CRT PFC/recipient spleen (X 103)c 
addedb 
lgM lgG lgA 
Spleen 3213 12,987 1456 
Spleen 10' 2759 9752 1339 
Bone marrow 176 587 136 
Bone marrow 10' 459 1459 406 
Peripheral lymph nodes 10' 1179 11,022 931 
Mesenteric lymph node 10' 5183 19,493 2543 
Peyer's patches 10' 1031 3905 1240 
Thymus 10' 31 188 64 
Blood 10' 56 159 43 
10' <0.2 <0.2 <0.2 
"Viable nucleated cells (2 X 107) or 0.25 ml blood were transferred 4 mo after iv priming Of 
sham-splenectomized mice with 4 X 108 SRBC. 
b Corticosteroid resistant thymocytes (CRT) were obtained from 6-wk-old mice ip injected 
with Dexamethasone-sodium-phosphate 2 days previously. 
c Arithmatic mean of the values obtained from five recipient mice. PFC-assay was done 7 days 
after cell transfer. 
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TABLE 7 
APPEARANCE OF B AND T MEMORY CELLS IN THE BONE MARROW OF MICE 
SPLENECTOMIZED OR SHAM-SPLENECTOMIZED BEFORE PRIMING WITH SRBC 
(SUMMARY OF RESULTS OF TABLES 2-6) 
Surgery Priming dose BandT 
memory cells 
Splenectomy 10' SRBC 
-• 
Sham-splenectomy 10' SRBC ++' 
Splenectomy 4 X 10' SRBC +' 
Sham-splenectomy 4 X 10' SRBC ++' 
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a No significantly increased response as compared with the bone marrow cells from nonprimed 
mice. 
b Greatly increased response. 
c Moderately increased response 
capacity to exhibit PFC activity m the bone marrow during the secondary re-
sponse (Fig. 5). 
Using isotopic labeling techniques it was demonstrated that the great ma-
jority of the bone marrow lymphocytes are generated in situ (19, 20). These 
small lymphocytes have a very rapid turnover: more than 80% become labeled 
after repeated ip injections of tritiated thymidine ('HTdR) for 4 days (19, 21). 
Theta positive cells (14, 18) as well as cells which can perform T cell functions 
(22, 23) are found to be very scarce in mouse bone marrow. About 50% of the 
marrow small lymphocytes show varying amounts of surface immunoglobulins 
(Ig) (24). The lymphocyte-like cells which lack theta-antigen, readily demon-
strate Ig or complement receptors on their surface are suggested to be predom-
inantly immature B lymphocytes (21, 25). Osmond and Nossal (21) recently 
studied the appearance of surface-Ig on short-lived bone marrow lymphocytes in 
mice. These authors obtained strong evidence that small lymphocytes in the 
marrow are initially Ig-negative but rapidly express increasing amounts of 
surface-Ig during differentiation and proliferation. Basten and co-workers ( 26) 
·using a radioactively labeled antigen "suicide" technique whereby cells binding 
the antigen are inactivated, have shown that, in conditions in which thymo-
cytes and spleen B cells are inactivated, bone marrow lymphocytes are un-
affected. This could be interpreted as suggesting that maturation to the antigen-
binding stage takes place predominantly after the cells have migrated from the mar-
row. This line of evidence is consistent with the hypothesis of Nieuwenhuis and 
Keuning (6) about the origin of the B cell system. Based upon a series of experi-
ments with rabbits they suggest that the B cell system is morphologically repre-
sented by all the follicular structures (including the marginal zone) in the body. 
The population of lymphoid cells in these follicular structures is of dual origin: 
( 1) directly bone marrow-derived (B1 cells) and involved in the formation of 
germinal centres; (2) indirectly-via germinal centre reactions-bone marrow-
derived (B 2 cells) and represented in the marginal zone cell system as anti-
body-forming cell precursors involved in the formation of plasma cells. This 
population of B2 cells would also include the B memory cells which are found 
to contribute to the recirculating lymphocyte pool (27, 28) and seed to the 
bone marrow (Table 7). Thus mouse bone marrow seems to contain two popu-
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lations of B cells: ( 1) probably immunoincompetent, short-lived cells, differen-
tiated in situ; (2) immunocompetent B memory cells, derived from secondary 
lymphoid organs. 
It is of interest that splenectomy before priming with 10' SRBC iv not only 
interfered with the appearance of B memory cells in the bone marrow, but also 
with their appearance in other lymphoid organs, including the thymus (com-
pare Tables 2-4). Apparently the appearance of B memory cells in the lymphoid 
organs throughout the body is caused by seeding from the spleen and not due 
to generation of these memory cells in these organs in situ. 
There is little doubt that memory tO thymus-dependent antigens is carried 
not only by B cells, but also by T cells. Limiting dilution experiments suggest 
that T cell memory constitutes an increase in the number of T cells (27). This 
view is supported by experiments reported here and by the observation that 
memory to the thymus-dependent antigen TIGAL (a synthetic polypeptide) is 
associated with increased numbers of specific antigen-binding T cells in the 
spleen (29). Experiments in which thymocytes were transferred into lethally 
irradiated recipients together with specific antigen show that under these cir-
cumstances T memory cells can be generated in the spleen ( 30, 31). However, 
such experiments do not provide evidence that under more physiological condi-
tions T memory cells are also generated in secondary lymphoid organs. In our 
experiments it was observed that splenectomy before priming with 107 SRBC 
iv can completely prevent the appearanc·e of T memory cells in the bone 
marrow, thus providing evidence that T memory cells indeed are generated in 
secondary lymphoid organs, as has been hypothesized by Miller and Mitchell 
(9). It would be of great interest to investigate in this experimental system 
whether such T memory cells are also absent in the recirculating lymphocyte 
pool. 
Experiments in which the DNA-synthesis of adoptively transferred thyrno-
cytes in the spleen of irradiated mice were correlated with their helper cell 
activity suggest that T cell mitosis is involved in the generation of T memory 
cells (31). ·Light and electron microscopic studies in our laboratory suggest 
that this proliferation and maturation proc-ess in the spleen occurs in the 
periarteriolar lymphatic sheath around and in close contact with interdigitating 
cells ( 32). 
The effect of splenectomy upon the appearance of B and T memory cells 
could be partly overcome by using an antigen dose as high as 4 X 10' SRBC 
(Table 7). It is known that small numbers of iv inoculated "Cr-labeled SRBC 
can reach the gut (33). Although immunization with 4 X 10' SRBC iv did 
not evoke the appearance of PFC in lymph nodes and Peyer's patches (1), it is 
possible that this antigen dose did induce the generation of B and T memory 
cells in these organs, since it is known that the development of B and T cell 
memory requires only small amounts of antigen (2, 34, 35). Therefore a 
plausible explanation for the appearance of B memory cells (in bone marrow, 
peripheral lymph nodes, mesenteric lymph node, Peyer' s patches, thymus, and 
blood) and T memory cells (at least in the bone marrow) in mice splenec-
tomized before priming with 4 X 10' SRBC iv is, that these memory cells are 
induced by small amounts of antigen reaching lymph nodes and gut-associated 
lymphoid ·tissue. However, an alternative explanation has also to be considered. 
It cannot be excluded that the bone marrow is in principle, like spleen and 
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lymph nodes, able to generate B memory cells, but that the generation of B 
memory cells in the bone marrow requires a higher antigen dose. Likewise it 
would be possible that high doses of antigen can induce the generation of T 
memory cells within the thymus. The presence of both interdigitating cells (36) 
and long-lived, potentially recirculating T lymphocytes (37) in the thymic 
medulla is consistent with this supposition. 
Cell transfer experiments reported in a previous paper (3) showed that 
thymocytes cannot enhance the adoptive· PFC response of immune spleen cells 
or immune bone marrow cells. From these experiments it was concluded that 
in both spleen and bone marrow the number of T memory cells was enough to 
give a maximal PFC response. In the present experiments CRT were used as a 
source of T cells to supplement lymphoid cell suspensions. Such cells are found 
to be better helper cells than normal thymocytes ( 38). We confirmed these 
results by showing that in contrast to normal thymocytes (3), CRT could 
enhance the adoptive PFC response of immune bone marrow cells (Tables 4-6). 
Apparently the number of T cells in the bone marrow of immune mice is not 
optimal for a maximal adoptive PFC response. This relative deficit of T cells 
was observed regardless of the origin of B and T memory cells, spleen-derived 
(Table 4) or derived from other lymphoid organs (Table 5). In spite of a 
different B/T ratio in these various lymphoid organs (39) and a preponderance 
.of T cells in the recirculating lymphocyte pool (28, 39) the relative deficit of T 
cells in the bone marrow seemed to be the same. Apparently the bone marrow 
determines the amount of, or the ratio between, the B and T cells which enter. 
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Antibody Formation in Mouse Bone Marrow 
V. THE RESPONSE TO THE THYMUS-INDEPENDENT ANTIGEN 
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Summary. The occurrence of plaque-forming cells (PFC) in mouse bone 
marrow was studied during primary and secondary response to the thy-
mus-independent antigen Escherichia £fill I ipopolysaccharide (LPS). 
Anti-LPS responses were induced by various doses of LPS. 
During the primary response doses of 1 and 10 ~g LPS intravenously 
(i.v.) were found to evoke a distinct PFC response in both spleen and 
bone marrow. The spleen contained the majority of PFC until about 
5 days after immunization. In the course of the reaction the number 
of PFC in the bone marrow rose to a level which equalled or sur-
passed the level in the spleen. LPS doses of 0.001, 0.01 and 0.1 pg 
i.v. only induced a PFC response in the spleen. Apparently there is 
a minimal threshold dose of LPS of about l ~g for PFC to appear in 
the bone marrow. 
The secondary response was studied in mice primed with 1 pg LPS 
i.v. and boosted with either 0.001, 0.1 or 10 pg LPS i.v. three 
months later. After each dose tested the PFC activity in the spleen 
was several times higher than during the primary response. As was 
observed in the primary response doses of 0.001 and 0.1 pg LPS i.v. 
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did not evoke a PFC response in the bone marrow. After boosting 
with 10 f-19 LPS i.v. a significant PFC response was found in spleen, 
bone marrow, thymus, lymph nodes, Peyer's patches and blood. From 
about 5 days after the booster injection the number of PFC in the 
bone marrow exceeded the total number found in all other lymphoid 
organs. The results are discussed in relation to the bone marrow PFC 
response to the thymus-dependent antigen sheep red blood cells. To 
this antigen a clear PFC response in the bone marrow is found only 
during the secondary response. 
INTRODUCTION 
Previous papers of this series on antibody formation in mouse bone marrow 
dealt with the plague-forming cell (PFC) response to the thymus-dependent 
sheep red blood cell antigen (SRBC). After the second injection of SRBC, 
but not after the first, a very distinct lgM-, lgG- and lgA-PFC activity 
was found in the bone marrow (Benner, Meima, van der Meulen and van 
Muiswinkel, 1974). Independent of the booster dose this activity in the bone 
marrow appeared to rise to a level which surpassed the total level of all the 
other lymphoid organs (Benner, Meima, van der Meulen and van Ewijk, 1974). 
Evidence was presented that cells producing anti -SRBC antibodies can be ge-
nerated within the bone marrow itself (Benner et al., 1974a). To initiate 
such a bone marrow PFC responSe to SRBC, the presence of specific memory 
cells seems to be required (Benner, Meima and van der Meulen, l974i Benner 
and van Oudenaren, 1975). Presence of the spleen was found to be essential 
for these memory cells to appear after intravenous (i.v.) priming with mode-
rate doses of SRBC (Benner and van Oudenaren, 1975). 
From the literature it is known that the thymus-independent antigen 
Brucella (Thorbecke, Asofsky, Hochwald and Siskind, 1961), in contrast to 
thymus-dependent antigens (Thorbecke et al., 196li Langevoort, Asofsky, 
Jacobson, de Vries and Thorbecke, 1963), can evoke antibody formation in 
rabbit bone marrow during the primary response. In view of these data it 
seemed worthwhile to study whether mouse bone marrow can also show PFC 
activity after primary immunization with a thymus-independent antigen. The 
antigen chosen was lipopolysaccharide (LPS) from Escherichia coli because 
antibody formation to this antigen does not require helper T cells (Andersson 
and Blomgren, 1971; M6ller and Michael, 1971) and no evidence has been 
presented so far that suppressor T cells play a regulatory role in the anti-
body response to LPS. We found that mouse bone marrow is able to show a 
distinct anti-LPS activity, even during the primary response. 
MATERIALS AND METHODS 
Mice 
(C57BL/Rij x CBA/Rij)F1 female mice, 16-20 weeks old were used. 
They were purchased from the Medical Biological Laboratory, Rijswijk, 
The Netherlands and the Laboratory Animals Centre of the Erasmus Univer-
sity, Rotterdam, The Netherlands. 
Antigen and immunization 
LPS from f.. coli 055:85, prepared according the phenol-extraction method 
(Westphal, Luderitz and Sister, 1952), was obtained from Difco Laboratories, 
Detroit, Michigan, U.S.A. Before use it was dissolved in a balanced salt 
solution (BSS), prepared according to Mishell and Dutton (1967). 
Mice were immunized by i.v. injection of doses of LPS ranging from 
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0.001 fJg - 100 1-'9 in 0.5 ml BSS. For secondary immunization mice received 
an i.v. booster injection 3 months after the first injection. 
Splenectomy 
Splenectomy and sham-splenectomy were performed l month before injec-
tion of LPS. Mice were anaesthetized by an intraperitoneal (i.p.) injection 
af 70 mg/kg body weight Nembutal (Abbott S.A., Saint-Remy-sur-Avre, 
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France). The incision was made in the left upper abdomen. For splenectomy 
the splenic blood vessels were tied in a single suture, then cut and the 
spleen removed. The incision was closed in two layers. There was no post-
operative mortality. 
Preparation of cell suspensions 
Cell suspensions were prepared in BSS as described previously (Benner et 
al. 1 1974a). Blood was obtained by cardiac puncture and immediately he-
parinized {5 U/ml). Thymi were collected 30 minutes after an i.p. injection 
with 0.1 ml of a l percent solution of carbochrome ink (Gurr Ltd., High 
Wycombe, Buckinghamshire, England) in BSS. This facilitated differentiation 
bet_ween thymus and adherent lymph nodes in order to avoid contamination 
of the thymocyte suspension. 
Isolation of nucleated cells from peripheral blood 
Nucleated cells were isolated from mouse blood using a modification of 
the Ficoll-lsopaque system described by Bllyum (1968). The Ficoll-lsopoque 
mixture was obtained by mixing 2 parts lsopaque (Nyegaard & Co., Oslo, 
Norway), 3 partS Ficoll (Pharmacia, Uppsala, Sweden) 9 per cent and 2 parts 
of a 3.5 per cent solution of bovine serum albumin in distilled water. Final 
density was 1.115 g/ml. Using this method at least 70 per cent of the nu-
cleated cells was recovered. A Coulter counter model B was used for counting 
nucleated cells isolated from peripheral blood. 
Cell counts 
Viable nucleated cells were counted in a haemocytometer using 0.2 per 
cent trypan blue in BSS as a diluent. 
Irradiation 
The recipient mice received 850 rad whole body irradiation generated in a 
Philips Muller MG 300 X-ray machine. Animals were irradiated in well-
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aerated circular Perspex cages. Physical constants of the irradiation were des-
cribed previously (Benner et al., 1974b). Irradiated control mice died in 
9-16 days. 
Cell transfer 
Recipients were injected i.v. with the appropriate cell suspension and 5 1-19 
LPS within 4 hours after irradiation. On the fourth day all mice were boosted 
with another 5 jJg LPS i.p. PFC in the spleen of recipient mice were deter-
mined 7 days after cell transfer1 since at that moment PFC activity in the re-
cipient spleen is maximal. Each group consisted of 5 mice. 
Assay far PFC 
PFC were determined according to the method of Cunningham and $zen-
berg (1968) with some modifications as described previously (Benner et al., 
l974a, 1975). SRBC coated with LPS were used as targets. Before use LPS 
(l rng/ml phosphate buffered saline (PBS), pH 8.0) was boiled for 2 hours 
at l20°C. Coating was performed by incubation of 0.3 ml washed and packed 
SRBC with 0.7 ml of the heat treated LPS solution at 37°( for 45 minutes. 
The coated cells were washed three times in PBS (pH 7.2) before use in 
the PFC assay. The guinea pig complement (Flow Laboratories, Rockville, 
U.S.A.) used in the plague assay was previously adsorbed with SRBC, mouse 
spleen cells and agarose. Adsorption with agarose (3 mg/ml guinea pig 
serum) was found to give excellent removal of anti-LPS antibodies (Zaalberg, 
personal communication). lgG and lgA producing anti-LPS PFC could not be 
detected at any time after primary and secondary immunization with LPS. 
Calculation of total bone marrow PFC activity 
Bone marrow PFC activity was determined in the femoral marrow. From the 
results of the femoral bone marrow the number of PFC present in the marrow 
of the whole animal was estimated using the data of Chervenick and co-
workers (1968), who showed that in mice one femur contains 5.9 per cent of 
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the total marrow. Comparison of the PFC responses evoked by fixed numbers 
of nucleated bone marrow cells from femur, tibia, humerus, rib and sternum 
(Table 1) indicated that anti-LPS PFC activity in various compartments of 
mouse bone marrow is about the same. 
TABLE 1 
Comparison of PFC Activity in Various Compartments of 
Mouse Bone Marrow During the Primary Response to LPS 
Source of 
bone marrow ce II s 
Femur 
Tibia 
Humerus 
Ribc 
Sternum c 
PFC/107 viable nucleated cellsa 
2,492b (1,419 - 4,376) 
3,415 (1,886 - 6, 181) 
2,937 (1,908 - 4,521) 
2,986 (1,644 - 5,425) 
2,960 (1,746 - 5,019) 
0 Mice were immunized with 10 }Jg LPS i.v. PFC-assay was 
done 5 days after immunization. 
bGeometric mean and 95% confidence limits. 
cMarrow cells from ribs and sternum were obtained by gently 
breaking of the bones with mortar and pestle. Cells were. 
separated from bone fragments by squeezing the suspension 
through a nylon-gauze filter with 30 fJm openings. 
Passive haemagglutination titres 
Anti-LPS antibody titres were assayed by means of a passive haemaggluti-
nation technique using a l per cent suspension of SRBC coated with LPS. The 
samples were tested in duplicate with the standard twofold dilution method 
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for the presence of 2-mercaptoethanol (2-ME) sensitive and 2-ME resistant 
antibodies. For determination of 2-ME resistant antibody titres, the sera were 
diluted v/v with 0.2 mol 2-ME. After incubation for 2 hours at room tempe-
rature, the sera were titrated according to the standard method. 
RESULTS 
Primary response to LPS 
Immunization of mice with 0.001, 0.01, 0.1, 1 and 10 ~g LPS i.v. evoked 
a PFC response in the spleen (Fig. 1 and 2). Independent of the antigen 
dose peak PFC activity was always found on the fourth day after immuni-
zation. After LPS doses of l and 10 f-19, but not after lower doses, PFC 
could also be detected in the bone marrow (Fig. 1). This PFC activity in 
the bone marrow equalled or surpassed the PFC activity in the spleen at 
5 days after immunization. In all other lymphoid organs tested no significant 
PFC activity was found at any time after a single dose of LPS. 
The absence of PFC activity in the bone marrow after 0.1 fJg or less LPS 
might be due to the elimination of antigen by the spleen. Therefore we 
also studied the response to 0.1 pg LPS in splenectomized mice. Such mice 
also showed no significant PFC activity in the bone marrow and no increase 
in the serum agglutination titre {Fig. 3). After i.v. immunization with doses 
LPS as low as 0.1 pg the spleen seems to be the only site of antibody 
formation. 
Secondary response to LPS 
The secondary response to LPS was studied in mice primed with 1 pg LPS i.v. 
and boosted with either 10, 0.1 or 0.001 ~g LPS i.v. 3 months later. After 
each dose tested the PFC activity in the spleen (Fig. 4) was much higher than 
during the primary response to that dose (compare Fig. 1, 2 and 4). Similar 
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Fig. 1. Number of PFC in mouse spleen (0) and bone 
marrow (e) after one injection of either 10 or 1 f-19 LPS i.v. 
In lymph nodes, Peyer 1s patches, thymus and blood no signi-
ficant PFC activity was found at any time after immunization. 
PFC-assay was done on pooled spleens. Each group consisted 
of at least 4 mice. 
to the primary response after doses of 0.1 and 0.001 ~g LPS i.v ., these doses 
did not evoke a PFC response in the bone marrow. After boosting with 10 1-'9 
LPS i.v. a PFC response was found not only in spleen, but also in bone marrow 
(Fig. 4), mesenteric lymph node, peripheral lymph nodes, Peyer 1s patches, thy-
mus and blood (Fig. 5). At about 5 days after this booster injection the number 
of PFC in the bone marrow exceeded the total number of PFC in all the- other 
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lymphoid organs. Although only a few PFC were found in the thymus, the 
response in this organ was more sustained thari in lymph nodes, Peyer 1s patches 
and blood. 
The influence of the priming dose of LPS on the appearance of B memory 
cells was studied by means of cell transfer experiments. Seven days after trans-
fer of 2 x 107 viable nucleated non-immune spleen cells, bone marrow cells or 
thymus cells together with 5 ~g LPS into lethally irradiated mice 49,500, 
11,250, and (a not significant number of) 175 PFC could be detected in the 
recipient spleen respectively. When the donor mice had been primed with 0.1, 
1, 10 or 100 fJ9 LPS i.v. 3 months before, spleen cells, bone marrow cells and 
thymus cells were able to evoke increased anti-LPS PFC responses in the re-
cipient spleen. The relationship between the priming dose and adoptive PFC 
response was found to be an optimum curve (Fig. 6). Doses LPS of l and 10 1-1g 
i.v. gave the best priming; l 1-19 was used in the experiments on secondary 
responses described above. 
lgM-
PFC/spleen 
105 
10 
days after injection 
15 
Fig. 2. Number of PFC in mouse spleen after one iniection of 
either 0.1 (0), 0.01 (0) or 0.001 (.6.) ~g LPS i.v. In bone 
marrow, lymph nodes, Peyer's patches, thymus and blood no 
significant PFC activity was found at any time after immuni-
zation. PFC-assay was done on pooled spleens. Each group 
consisted of at least 4 mice. 
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The relatively low adoptive PFC response evoked by cells from mice primed 
with 100 ~g LPS i.v. (Fig. 6) is temporary. This was shown by transferring 
spleen cells, bone marrow cells and thymus cells from su_ch mice 6 months 
after priming. At that time adoptive PFC responses were much higher than after 
3 months (Table 2). Apparently high doses LPS i.v. result initially in a smaller 
number of B memory cells than do moderate doses of LPS. Hanna and Peters 
(1971) reported similar results for the appearance of B memory cells in the 
spleen after immunization with SRBC. These authors ascribe the smoll numbers 
of B memory cells after high doses of antigen to an exhaustion of this cell 
population, due to maturation of newly formed B memory cells into antibody-
forming cells. 
DISCUSSION 
After primary immunization of rabbits with the thymus-independent antigen 
12 
8 
4 
0,~--------,--------.--------.--------
0 5 10 15 
days after injection 
Fig. 3. Agglutinating antibody titres in the sera of mice sham-
splenectomized (0) or splenectomized (0) 1 month before 
immunization with 0.1 ~g LPS i.v. The anti-LPS antibodies 
were 2-ME sensitive. 
JgM-
PFC/organ 
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• 
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• 
0 
0 
1034-----,----.---~---~~,______,_..~,---
0 5 10 15 20 35 70 
days after second injection 
Fig. 4. Number of PFC in mouse spleen and bone marrow after 
two injections of LPS. Mice were primed with 1 1-'g LPS i.v. 
and boosted with either 10 (0, spleen; e, bone marrow), 
0.1 (0, spleen) or 0.001 (Ll., spleen) ~g LPS i.v. 3 months 
later. After boosting with 10 ~g LPS i.v. PFC activity was 
found not only in spleen and bone marrow, but also in 
mesenteric lymph node, peripheral lymph nodes, Peyer1s patches, 
thymus and blood (see Fig. 5). After boosting with 0.1 and 
0.001 1-'9 LPS i.v. no significant PFC activity was found in 
other lymphoid organs than spleen. 
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Brucella, bone marrow cells of these animals cultured in vitro were found to 
release specific antibodies (Thorbecke et al., 1961 ). As far as antibody for-
mation in vivo to thymus-independent antigens has been studied by means of 
the plaque "lssay, most frequently PFC activity has been determined in spleen 
and lymph nodes. Only a few authors have studied the bone marrow as a source 
of PFC (Landy, Sanderson and Jackson, 1965; Baker, Stashak, Amsbaugh and 
Prescott, 1971). Landy et al. (1965) found small but significant numbers of PFC 
in the bone marrow of rabbits after primary immunization with Salmonella 
enteritidis polysaccharide. On the other hand Baker et al. (1971) could not 
detect any PFC activity in mouse bone marrow during the primary response to 
an optimal dose of type Ill pneumococcal polysaccharide (Sill). 
12 
!gM-
PFC/organ 
104 
days after second injection 
Fig. 5. Number of PFC in mouse mesenteric lymph node {.), 
peripheral lymph nodes (0), ?eyer's patches (0), thymus (e), 
and blood (...._) after two injections of LPS. Mice were primed 
with 1 ~g LPS i.v. and boasted with 10 ~g LPS i.v. three 
months later. The organs were obtained from the same mice 
used to determine PFC activity in spleen and bone marrow 
(Fig. 4). 
The results presented in this paper show that mouse bone marrow can ex-
hibit a clear PFC activity to the thymus-independent antigen h ££.!.i LPS, 
bath during the primary {Fig. 1) and the secondary response (Fig. 4 ). In pre-
vious papers of this series (Benner et al., 1974a; 1974c; 1975) it has been 
shown that mouse bone marrow can contain large numbers of PFC to the thy-
mus-dependent SRBC antigens, however, only during the secondary, and not 
during the primary response. Specific memory cells are probably required for 
the appearance of anti-SRBC PFC in the bone marrow during the secondary 
response (Benner et al., 1974b; 1975). Splenectomy experiments (Benner et 
al., 1974a; Benner and van Oudenaren, to be published) provided evidence 
for the !.u ~ differentiation of non-antibody-producing cells into anti-SRBC 
and anti-LPS antibody forming cells in mouse bone marrow. The most tempting 
explanation why anti-SRBC PFC activity in the bone marrow is a memory-
dependent phenomenon, in contrast to anti-LPS bone marrow PFC activity, 
is related to the difference in thymic dependency between these two antigens. 
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While after immunization with LPS B cells which are normally present in mouse 
bone marrow might differentiate without T cell help into PFC l!l situ, SRBC-
specific B cells are unable to do so because they need the presence of T 
memory cells. 
It is notable that anti-LPS PFC responses in the bone marrow appear only 
after high doses of antigen. This observation and the absence of PFC activity 
in the bone marrow after i.p. immunization with an optimal dose of Sill 
(Baker et al., 1971) suggest that antibody formation to these thymus-independent 
antigens in the bone marrow is not only dependent on the presence of the 
appropriate B cells. !D. .Y.l!..!:2 experiments suggest that macrophages are involved 
lgM-
PFC/spleen 
106 
103'-t--r---r---.----.----
0.1 10 100 
,ug LPS used for priming 
Fig. 6. Adoptive PFC response of spleen, bone marrow and 
thymus cells 3 months after priming with various doses LPS 
i.v. (0) Spleen cells, (e), bone marrow cells and (0) 
thymus cells. Viable nucleated cells (2 x 107) were trans-
ferred to lethally irradiated syngeneic mice together with 
5 fig LPS. Each group consisted of 5 recipient mice. PFC-
assay was done on pooled spleens 7 days after cell transfer. 
Transferred spleen cells, bone cells and thymus cells from 
non-immune mice evoked 49,500, 11,250 and 175 PFC re-
spectively. 
14 
in antibody formation to LPS (Bona, Robineaux, Heuclin and Astesana, 1973) 
and Slll (Aaskav and Halliday, 1971). The appearance of anti-LPS PFC in the 
bone marrow after immunization with 1 or 10 ~g LPS (Fig. 1 and 4) might 
therefore be due to interference by LPS with the reticuloendothelial system 
(RES). Benacerraf and Sebestyen (1957) showed that doses of 10 ~g LPS i.v. 
cause a transitory depression of the phagocytic activity of the RES. Within 
one day this depression is followed by a period of increased phagocytic acti-
TABLE 2 
Adoptive PFC Response by Spleen, Bone Marrow and Thymus 
Cells 3 and 6 Months after Priming with 100 ~g LPS i.v. 
Cells transferred from 0 
Spleen 
Bone marrow 
Thymus 
PFC/recipient 
3 months 
272,900 
58,100 
3,200 
b 
spleen 
6 months 
872,500 
179,250 
8,025 
0 Viable nucleated cells (2 x 1l) and 5 ~g LPS were trans-
ferred to lethally irradiated syngeneic mice. 
b PFC-assay was done on pooled spleens 7 days after cell 
transfer. Each group consisted of 5 recipient mice. Figures 
from a representative experiment. 
vity. When the presentation of antigen to lymphocytes in the bone marrow is 
the limiting factor for initiation of an anti-LPS PFC response in situ, stimula-
tion of the phagocytic activity of the RES probably accounts for the appearance 
of PFC in the bone marrow after immunization with relatively high doses of 
LPS. 
It is of interest to compare the minimal threshold antigen dose of LPS and 
15 
SRBC in spleen and bane marrow. The threshold dose of LPS for the bone 
marrow was about a thousand times higher than for the spleen. Such a great 
difference in the threshold antigen dose for spleen and bone marrow was not 
appearent during the secondary response to SRBC (Benner et al., 1974c). 
Several causes may account for this difference. In our opinion the most pro-
bable ones are related to the presentation of the antigen to lymphocytes in 
these organs with an anatomically so different structure: 
(l) In contrast to SRBC, LPS is a polymeric antigen and is composed of much 
smaller particles (Shands, 1971). Therefore red blood cells might be more 
susceptible to antigen-processing mechanisms in the bone marrow than LPS. 
(2) LPS only evokes the production of lgM-antibodies; SRBC, however, can 
also evoke the formation of lgG-antibodies which have a much longer half-
life and are better opsonins than lgM (Spiegelberg, 1974). At the moment of 
the second injection of SRBC opsonic antibodies from the primary response 
cause an optimal antigen-processing in the bone marrow. On the other hand, 
when mice receive a primary injection of LPS or a second one 3 months later, 
littLe or no specific lgM is present. Consequently antigen-processing within 
the bone marrow could be deficient. 
In some respects there is a striking similarity between the shape of the 
spleen and bone marrow PFC curves during the secondary response to SRBC 
(Benner et al., 1974a; 1974c; 1975) and the response to 10 ~g LPS. For both 
antigens the bone marrow PFC response is characterized by (1) a delayed 
appearance of PFC as compared with the spleen, and (2) a much higher PFC 
activity than in all other lymphoid organs together during the second phase 
of the response. The underlying regulating mechanisms of these phenomena are 
unclear. The delay of appearance of PFC in the bone marrow might be related 
to differences in antigen processing between spleen and bone marrow. Alter-
natively this delayed appearance of PFC might be due to a time-consuming 
migration of cells involved in the bone marrow PFC response into this organ 
during the first phase of the response. Although in previous papers (Benner 
et al., 1974a; 1975) migration of PFC from peripheral lymphoid organs into 
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the bone marrow could be excluded as the underlying cause for PFC activity 
in the bone marrow, the possibility of immigration in the bone marrow of cells 
triggered to give a PFC response has to be considered. The high bone marrow 
PFC activity during the second phase of the response is possibly due to one or 
more local factors which enhance the differentiation into PFC within the bone 
marrow. Recently it was reported that bone marrow cells can synthesize a 
humoral factor which enhances the PFC response in cultures of lymph node 
cells obtained from immune donors at the peak of the productive phase of 
antibody formation {Petrov, Mikhajlova, Stepanenko and Zakharova, 1975). 
This factor might account for the high PFC activity observed in the bone marrow 
during the· second phase of the response. 
The appearance of B memory cells in the thymus after i .v. immunization 
with LPS ·(Fig. 6) is consistent with previous experiments with SRBC as antigen 
(Jehn and Karlin, 1971; Benner, Meima and van der Meulen, l974d). The pre-
sence of B memory cells in the thymus coincides with the capacity of this 
organ to" exhibit PFC activity upon subsequent stimulation with the antigen 
used for priming. This suggests that the appearance of PFC in the thymus 
during the secondary response is due to an l!:! situ differentiation of B memory 
cells into PFC. Thymic PFC responses can only be evoked by high doses of 
antigen (Fig. 5; Benner et al., 1974c) probably because antigens scarcely 
enter the thymus tissue (Kater, 1970). 
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